All clinical trials on the European Union Clinical Trials Register (EUCTR) must report their results in the registry within a year of completion. This site tracks who's doing this and who isn't. Learn more »
These trials completed more than 12 months ago and should have reported results. Some have, some have not.
These trials are not yet due to report results: some are ongoing, some completed within the past 12 months.
These trials have problematic data on the registry. Details why »
| Status | Trial ID | Title | Completion date | Category |
|---|---|---|---|---|
| Reported results | 2004-000023-15 | A Comparison of CS-747 and Clopidogrel in Acute Coronary Syndrome Subjects who are to Undergo Percutaneous Coronary Intervention | 2007-07-22 | due-trials |
| Reported results | 2004-000028-34 | A randomised Phase 3 Trial of ALIMTA and Cisplatin versus GEMZAR and Cisplatin in Patients with locally advanced or metastatic Non-Small-Cell Lung Cancer | 2008-03-10 | due-trials |
| Reported results | 2004-000167-95 | Duloxetine Versus Placebo in the Prevention of Recurrence of Major Depressive Disorder | 2008-01-23 | due-trials |
| Reported results | 2004-000349-40 | Efficacy of Exenatide Compared with Insulin Glargine in Patients with Type 2 Diabetes Using Metformin or Sulfonylurea for Whom Insulin is the Next Appropriate Therapy | 2005-10-18 | due-trials |
| Not reported | 2004-000573-54 | An Open-Label Study Examining the Long-Term Safety of Exenatide Given Twice Daily to Patients with Type 2 Diabetes Mellitus | 2009-04-07 | due-trials |
| Reported results | 2004-000577-65 | A Phase 3, randomized, open label, comparator-controlled, parallel-group, multicentre study to compare the effects of exenatide and insulin glargine on beta cell function and cardiovascular risk marke... | 2009-12-03 | due-trials |
| Completed, but no date, and reported results | 2004-000580-10 | Effect of Tadalafil on the Quality of Life and Sexual Life Satisfaction in Erectile Dysfunction (ED) Patients Previously Treated with other Oral ED therapy | bad-data | |
| Reported results | 2004-000589-11 | Protocol F1D-MC-HGKR. Olanzapine Plus Carbamazepine Versus Carbamazepine Alone in the Treatment of Manic or Mixed Episodes Associated with Bipolar I Disorder | 2006-06-28 | due-trials |
| Reported results | 2004-000691-13 | A phase 2 study of ALIMTA plus doxorubicin administered every 21 days in patients with advanced breast cancer | 2007-09-24 | due-trials |
| Reported results | 2004-000815-25 | A randomized phase 3 study of two doses of ALIMTA in patients with locally advanced or metastatic Non-Small Cell Lung Cancer who have failed a prior platinum-containing chemotherapy. | 2008-04-15 | due-trials |
| Completed, but no date, and reported results | 2004-000894-67 | The Effect of Teriparatide on Distal Radius Fracture Healing | bad-data | |
| Reported results | 2004-000986-37 | An Open-Label Study of Intramuscular Olanzapine Depot in Patients With Schizophrenia or Schizoaffective Disorder | 2010-12-31 | due-trials |
| Completed, but no date, and reported results | 2004-001033-41 | A Randomized, Double-Blind, Parallel-Design, Placebo-Controlled Study to Evluate the Efficacy and Safety of Tadalafil (2.5 mg e 5 mg) administered once daily to men with diabetes mellitus and erectile... | bad-data | |
| Reported results | 2004-001237-42 | Open-Label Duloxetine Extension phase in Patients Who Have Completed the F1J-MC-HMDG Clinical Trial Fase de extensión abierta con duloxetina en aquellos pacientes que hayan finalizado el ensayo clíni... | 2006-08-25 | due-trials |
| Ongoing | 2004-001308-11 | Optimal Treatment Duration with Olanzapine following Remission of Manic or Mixed Episode. An Open-Label, Randomized Trial Comparing Two Treatment Strategies ?Duración óptima del tratamiento con O... | not-yet-due | |
| Reported results | 2004-001319-71 | A Phase IIIb Study to Determine Efficacy and Safety of Extended Drotrecogin Alfa (Activated) Therapy in Patients With Persistent Requirement for Vasopressor Support After 96-Hour Infusion With Commerc... | 2007-05-08 | due-trials |
| Reported results | 2004-001482-17 | Olanzapine Versus Divalproex and Placebo in the Treatment of Mild to Moderate Mania Associated with Bipolar I disorder. | 2006-12-13 | due-trials |
| Reported results | 2004-001562-41 | Efectos del Arzoxifeno en la incidencia de fracturas vertebrales y en la incidencia de cáncer de mama invasivo en las mujeres posmenopáusicas con osteoporosis o con baja densidad ósea Effects of Arz... | 2009-11-30 | due-trials |
| Reported results | 2004-002425-52 | A Phase 3 Study of Pemetrexed Plus Best Supportive Care versus Best Supportive Care As Maintenance Therapy Immediately Following Induction Treatment For Advanced Non-Small Cell Lung Cancer | 2013-12-03 | due-trials |
| Completed, but no date, and reported results | 2004-002537-39 | Phase II Trial of Neoadjuvant ALIMTA plus Cisplatin followed by Surgery and Radiation in the Treatment of Pleural Mesothelioma Studio di Fase II con ALIMTA piu` Cisplatino in Neoadiuvante seguiti ... | bad-data | |
| Reported results | 2004-002626-22 | Duloxetine 60 to 120 mg Once Daily Compared with Placebo in the Prevention of Relapse in Generalized Anxiety Disorder | 2007-03-14 | due-trials |
| Exempt, with results | 2004-002782-20 | A Phase 1 and 2 Clinical Trial of ALIMTA (Pemetrexed) in Combination with Carboplatin in Patients with Recurrent Ovarian or Primary Peritoneal Cancer | 2010-02-23 | not-yet-due |
| Reported results | 2004-002784-24 | A Randomized, Double-Blind, Phase 2 Study of Two Doses of Pemetrexed in the Treatment of Platinum-Resistant, Epithelial Ovarian or Primary Peritoneal Cancer | 2007-04-25 | due-trials |
| Reported results | 2004-003941-42 | A Randomised, Double Blind Placebo Controlled Study of the Broader Efficacy of Atomoxetine Hydrochloride in the Treatment of Attention-Deficit/Hyperactivity Disorder (ADHD) in Swedish Children and Ado... | 2006-08-21 | due-trials |
| Reported results | 2004-004088-31 | A Randomized Double-Blind, Placebo-Controlled Clinical Trial of Efficacy and Safety of Atomoxetine up to 12 weeks in Newly Diagnosed Children and Adolescents Outpatients with Attention-Deficit/Hypera... | 2008-02-06 | due-trials |
| Exempt, with results | 2004-004149-16 | Phase 1/2 Study of Biweekly ALIMTA plus Cisplatin in patients with Locally Advanced, non-Resectable or Metastatic Urothelial Cancer | 2008-04-30 | not-yet-due |
| Reported results | 2004-004160-67 | Effect of Duloxetine on Valsalva Leak Point Pressure and Quantitative Rhabdosphincter Electromyography Measures in Women with Stress Urinary Incontinence | 2008-07-03 | due-trials |
| Reported results | 2004-004960-64 | A Comparison of Duloxetine Hydrochloride, Venlafaxine Extended Release, and Placebo in the Treatment of Generalized Anxiety Disorder | 2007-01-24 | due-trials |
| Reported results | 2004-005068-26 | A Phase 2 Study of Oral Enzastaurin HCl in Patients with Metastatic Colorectal Cancer | 2008-03-06 | due-trials |
| Reported results | 2005-000021-32 | A Randomized Phase 2 Trial of Doxorubicin plus Pemetrexed followed by Docetaxel, versus Doxorubicin plus Cyclophosphamide followed by Docetaxel, as Neoadjuvant Treatment for Early Breast Cancer | 2011-03-17 | due-trials |
| Reported results | 2005-000515-95 | Differential Effects of Teriparatide and Strontium Ranelate on Bone Remodeling and Formation in Postmenopausal Women with Osteoporosis: A Histomorphometric Study | 2006-01-24 | due-trials |
| Reported results | 2005-000566-40 | A Pivotal Long-Term, Open-Label, Parallel Study of the Efficacy and Safety of Human Insulin Inhalation Powder in Patients with Type 1 Diabetes Mellitus | 2008-05-28 | due-trials |
| Reported results | 2005-000900-15 | The effect of Ruboxistaurin on Clinically Significant Macular Edema in Patients with Diabetes Mellitus, as assessed by Optical Coherence Tomography | 2011-07-14 | due-trials |
| Reported results | 2005-001524-37 | Duloxetine 60/120 mg Versus Placebo in the Treatment of Fibromyalgia Syndrome | 2007-06-27 | due-trials |
| Completed, but no date, and reported results Terminated | 2005-001527-11 | A Pivotal, Open-Label, Parallel Study to Evaluate the Safety and Efficacy of Human Insulin Inhalation Powder (HIIP) Compared to Injectable Insulin in Patients With Diabetes and COPD or Asthma | bad-data | |
| Completed, but no date, and reported results Terminated | 2005-001545-42 | A Randomized Phase III Trial of Gemcitabine and Docetaxel versus Gemcitabine and Paclitaxel in Patients with Metastatic Breast Cancer: a comparison of different schedules STUDIO RANDOMIZZATO DI FAS... | bad-data | |
| Completed, but no date, and reported results | 2005-001750-25 | Efficacy and Safety of Somatropin in Combination with Leuprorelin Compared to Somatropin Alone and to an Untreated Control Group in Pubertal Children with Idiopathic Short Stature | bad-data | |
| Reported results | 2005-002115-24 | Complaints Associated with Use of the Prefilled Pen B When Used by Patients with Type 2 Diabetes on Twice-Daily Insulin Therapy | 2006-04-26 | due-trials |
| Reported results | 2005-002174-30 | The Use of Nuclear Scintigraphy to Evaluate the Anabolic Effects of Teriparatide on the Skeleton in Postmenopausal Women in Osteoporosis | 2009-09-25 | due-trials |
| Reported results | 2005-002279-33 | Tratamiento con Alimta (Pemetrexed) y cisplatino como tratamiento neoadyuvante en el cancer no microcitico de pulmon | 2007-12-20 | due-trials |
| Ongoing | 2005-002430-34 | Efectos del bloqueo 5HT2A en pacientes deprimidos con respuesta inadecuada al tratamiento antidepresivo | not-yet-due | |
| Exempt, with results | 2005-002660-29 | A Phase 1b/2 Multiple-Dose Safety and Pharmacokinetic/Pharmacodynamic Study of LY2189102 in Patients with Rheumatoid Arthritis | 2007-11-19 | not-yet-due |
| Reported results | 2005-002692-33 | A Randomized, Double-Blind, Placebo-Controlled Phase 3 Study of the Phosphodiesterase Type 5 (PDE5) Inhibitor Tadalafil in the Treatment of Patients with Pulmonary Arterial Hypertension | 2008-08-16 | due-trials |
| Reported results | 2005-002844-24 | - Estudio doble ciego de extensión para evaluar la seguridad y eficacia a largo plazo del inhibidor de la fosfodiesterasa tipo 5 (PDE5) tadalafilo en el tratamiento de pacientes con hipertensión arter... | 2012-02-27 | due-trials |
| Reported results | 2005-002911-26 | A Randomized Phase 2 Study of Pemetrexed in Combination with Cisplatin or Carboplatin as Adjuvant Chemotherapy in Patients with Completely Resected Stage Ib or II Non-Small Cell Lung Cancer | 2013-07-30 | due-trials |
| Exempt, with results | 2005-003718-14 | Estudio fase I/II de quimioterapia con la combinación de Pemetrexed y Cisplatino concomitante con radioterapia seguida de quimioterapia de consolidación con Pemetrexed en pacientes con cáncer de pulmó... | 2010-08-06 | not-yet-due |
| Reported results | 2005-004157-99 | A Randomized, Open-Label Study Comparing the Effects of Olanzapine Pamoate Depot with Oral Olanzapine on Treatment Outcomes in Outpatients with Schizophrenia | 2009-09-29 | due-trials |
| Reported results | 2005-004188-50 | Maintenance of Effect of Duloxetine 60 mg Once Daily in Patients with Diabetic Peripheral Neuropathic Pain | 2007-10-30 | due-trials |
| Reported results | 2005-004627-18 | A Randomized Phase 3 Study of Enzastaurin versus Lomustine in the Treatment of Recurrent, Intracranial Glioblastoma Multiforme | 2014-08-19 | due-trials |
| Reported results | 2005-004630-41 | A Phase 3 Clinical Study to Investigate the Prevention of Relapse in Lymphoma Using Daily Enzastaurin | 2013-07-31 | due-trials |
| Reported results Terminated | 2005-004747-64 | A Phase 3, Open-Label, Parallel Group Study to Evaluate the Efficacy and Safety of Human Insulin Inhalation Powder HIIP Compared to Preprandial Injectable Insulin in Insulin-Na ve Patients with Type... | 2008-06-03 | due-trials |
| Reported results | 2005-004963-42 | Estudio DURABLE: Evaluación de la DURAbilidad de la eficacia de insulina Basal frente a insulina Lispro de baja mEzclaDurabilidad de la insulina lispro de baja mezcla (insulina lispro LM) administrada... | 2010-01-25 | due-trials |
| Reported results Terminated | 2005-004966-17 | PPAR Alpha (LY518674): a Phase 2 Dose-Response Study to Evaluate the Blood Pressure-Lowering Effect in Essential Hypertension | 2006-09-29 | due-trials |
| Listed as ongoing, but also has a completion date | 2005-005219-36 | A Phase 2 Single-Arm Study of Gemcitabine in Combination with Oxaliplatin in Pediatric Patients with Relapsed or Refractory Neuroblastoma or Miscellaneous Solid Non-CNS Tumors | 2006-02-21 | bad-data |
| Reported results | 2005-005258-29 | The Effect of Teriparatide Compared with Risedronate on Back Pain in Postmenopausal Women with Osteoporotic Vertebral Fractures | 2010-06-23 | due-trials |
| Reported results | 2005-005292-15 | A Pharmacokinetic and Pharmacodynamic Comparison of Prasugrel (LY640315) versus Clopidogrel in Subjects with Stable Atherosclerosis | 2006-12-06 | due-trials |
| Reported results Terminated | 2005-005381-37 | A Phase 3, Open-Label, Parallel Group Treatment Concordance Study to Compare Insulin Use and Its Effect on Glycemic Control in Patients with Type 2 Diabetes Mellitus: Two Populations with Different I... | 2008-01-05 | due-trials |
| Reported results | 2005-005448-21 | Long-Term Treatment with Exenatide versus Glimepiride in Patients with Type 2 Diabetes Pretreated with Metformin | 2011-03-30 | due-trials |
| Reported results | 2005-005535-10 | A Phase 2 study of ALIMTA in solid tumor patients with stable third-space fluid | 2009-03-20 | due-trials |
| Completed, but no date, and reported results | 2005-005701-32 | An Open-Label Study of the Efficacy of Atomoxetine Hydrochloride on Quality of Life of Children and Adolescents with Attention-Deficit/Hyperactivity Disorder with or without comorbid conditions | bad-data | |
| Reported results | 2005-005929-62 | A Feasibility study of Pemetrexed single agent and folic acid given as neoadjuvant treatment in patients with resectable rectal cancer | 2009-06-05 | due-trials |
| Reported results | 2005-006164-59 | An Open Label Study Comparing Exenatide with Basal Insulin in Achieving an HbA1c of <_7.4% with Minimum Weight Gain, in Type 2 Diabetes Patients who are not Achieving Adequate HbA1c Control on Oral An... | 2008-04-16 | due-trials |
| Reported results | 2006-000247-26 | A Phase 3, Open-Label, Three-Group Parallel Study to Evaluate the Efficacy and Safety of Human Insulin Inhalation Powder (HIIP) in Patients with Type 2 Diabetes Treated with Once-Daily Insulin Glargin... | 2008-11-24 | due-trials |
| Trial is outside EEC, and reported results | 2006-000304-16 | A Randomized, Double-blind Comparison of Atomoxetine Hydrochloride and Placebo for Symptoms of Attention-Deficit/Hyperactivity Disorder in Children and Adolescents With Autism Spectrum Disorder. | bad-data | |
| Reported results | 2006-000441-19 | A Randomized Phase II Study of two chemotherapy regimens, Pemetrexed-Carboplatin, and Gemcitabine-Vinorelbine, in Anthracycline and Taxane Pretreated Advanced Breast Cancer Patients | 2010-08-27 | due-trials |
| Reported results | 2006-000497-80 | A Phase 3, Open-Label, Parallel Group Study to Evaluate the Efficacy of Preprandial Human Insulin Inhalation Powder HIIP Compared to Preprandial Injectable Insulin in Patients with Type 1 Diabetes M... | 2008-05-27 | due-trials |
| Reported results | 2006-000813-39 | Prasugrel in comparison to Clopidogrel for Inhibition of Platelet Activation and Aggregation (PRINCIPLE) - TIMI 44 | 2007-06-20 | due-trials |
| Reported results | 2006-000889-36 | A Double-blind, Randomized, Placebo-controlled Multicentre Phase II Study of Maintenance Enzastaurin Following Whole Brain Radiation Therapy in the Treatment of Brain Metastases from Lung Cancer | 2011-02-01 | due-trials |
| Reported results | 2006-001173-14 | A Randomised Phase 3 Trial of Alimta (pemetrexed) and Carboplatin versus Etoposide and Carboplatin in Extensive-Stage Small Cell Lung Cancer. | 2008-06-06 | due-trials |
| Completed, but no date, and reported results | 2006-001470-25 | Randomisierte, doppelblinde Studie zum Vergleich neuropsychologischer Effekte von Atomoxetin gegen Placebo im Tagesverlauf bei Kindern mit Aufmerksamkeitsdefizit-/Hyperaktivitätsstörung unter Anwendun... | bad-data | |
| Reported results | 2006-001471-37 | A Randomized, Double-Blind Comparison of Atomoxetine versus Placebo in Children and Adolescents with Attention-Deficit/Hyperactivity Disorder and Comorbid Oppositional Defiant Disorder | 2009-01-23 | due-trials |
| Completed, but no date Terminated | 2006-001721-26 | The Genetics and Neuroendocrinology of Short Stature International Study (GeNeSIS) | bad-data | |
| Completed, but no date, and reported results | 2006-001836-32 | Pemetrexed monochemotherapy in patients with locally advanced or metastatic Non Small Cell Lung Cancer. A pilot study to define the best dosing schedule for a planned phase II randomized trial. | bad-data | |
| Trial is outside EEC, and reported results | 2006-001866-18 | A Randomized, Double-Blind, Crossover Comparison of Atomoxetine and Placebo in Child Outpatients With Attention-Deficit/Hyperactivity Disorder, Reading Disorder, or Comorbid Attention-Deficit/Hyperact... | bad-data | |
| Completed, but no date, and reported results | 2006-001938-41 | Effect of Exenatide plus Metformin vs. Premixed Human Insulin Aspart plus Metformin on Glycemic Control and Hypoglycemia in Patients with Inadequate Control of Type 2 Diabetes on Oral Antidiabetic Tre... | bad-data | |
| Reported results | 2006-001958-27 | A Randomized, Double-Blind, Placebo-Controlled, Parallel-Design, 5-Group, Multinational Study to Evaluate the Efficacy, Dose Response, and Safety of Tadalafil Once-a-Day Dosing for 12 Weeks in Men ... | 2009-05-14 | due-trials |
| Reported results | 2006-001985-17 | An Open-label, Single Arm, Phase 2 Study of Rituximab, Gemcitabine, and Oxaliplatin plus Oral Enzastaurin as Treatment for Patients with Relapsed Diffuse Large B-Cell Lymphoma | 2012-11-05 | due-trials |
| Reported results | 2006-001987-22 | The Comparison of the Efficacy and Safety of Arzoxifene versus Raloxifene in Postmenopausal Women with Osteoporosis. | 2008-07-01 | due-trials |
| Reported results | 2006-002112-99 | A Phase 2 Study to Evaluate Dose and Duration of Treatment of Drotrecogin Alfa (Activated) Using Serial Measurements of Protein C in Patients with Severe Sepsis and Multiple Organ Dysfunction | 2009-09-30 | due-trials |
| Reported results | 2006-002316-10 | A Randomized, Phase 2, Placebo-Controlled, Double-Blinded Study With and Without Enzastaurin in Combination With Paclitaxel and Carboplatin as First-Line Treatment, Followed by Maintenance Treatment i... | 2012-07-11 | due-trials |
| Reported results | 2006-002321-23 | A Phase 2 Study of LY573636 Administered a san Intravenous Infusion on Day 1 of a 21-Day cycle as third-line Treatment in patients with unresectable, metastatic non-Small Cell lung cancer | 2008-10-13 | due-trials |
| Ongoing | 2006-002519-28 | Ensayo PRIME DT2: Regímenes prandiales-basales de Insulina para mejorar la glucemia post-pandrial en Diabetes Tipo 2.Comparación de dos enfoques con terapia basal y en bolo en pacientes con Diabetes t... | not-yet-due | |
| Reported results | 2006-002618-37 | A Randomized, Double-Blind, Cross-Over Study Comparing the Pharmacodynamic Response in Subjects with Acute Coronary Syndrome Receiving 14 Days 10-mg Maintenance Dose Prasugrel (LY640315) versus 14 Day... | 2007-10-29 | due-trials |
| Reported results | 2006-002818-35 | A Randomized Phase 2 Study of Pemetrexed in Combination with Cisplatin or Carboplatin in the First Line Therapy of Advanced NSCLC | 2009-04-20 | due-trials |
| Exempt | 2006-002893-23 | An Open Label Single Arm Phase 1b/2 Study with Pharmacokinetic Sampling to Evaluate LY2181308 in Patients with Advanced Hepatocellular Carcinoma | 2008-08-08 | not-yet-due |
| Reported results | 2006-002922-51 | Tadalafil 5 mg Once a Day Compared to Placebo in Improving Erectile Dysfunction and Sexual Quality of Life | 2008-01-03 | due-trials |
| Reported results | 2006-002999-17 | A Phase 3, Open-Label, Parallel-Group Study to Compare Two Dosing Algorithms for Preprandial Human Insulin Inhalation Powder (HIIP) in Insulin-Naïve Patients with Type 2 Diabetes Mellitus | 2008-05-14 | due-trials |
| Exempt, with results | 2006-003007-39 | Phase I/II Study of Concurrent Cisplatin, Pemetrexed, and Radiotherapy for Limited Stage Small Cell Lung Cancer | 2008-05-30 | not-yet-due |
| Not reported | 2006-003076-35 | Treatment Strategies in Patients with Type 2 Diabetes Mellitus Not Achieving Glycemic Control while on Therapy with Premixed Insulin Analogues and Metformin: A Comparison of Insulin Lispro MM Intensi... | 2009-03-31 | due-trials |
| Reported results | 2006-003158-12 | A Randomized Phase 3 Study of Pemetrexed in Combination with Cisplatin Versus Cisplatin Monotherapy in Patients with Recurrent or Metastatic Head and Neck Cancer | 2010-03-17 | due-trials |
| Reported results | 2006-003484-31 | Effect of Duloxetine 60 mg to 120 mg Once Daily in Patients with Chronic Low Back Pain | 2008-10-17 | due-trials |
| Reported results | 2006-003485-33 | Duloxetine 60 to 120 mg versus Placebo in the Treatment of Patients with Osteoarthritis Knee Pain | 2008-05-04 | due-trials |
| Reported results | 2006-004486-34 | An Open-Label Study of Oral Enzastaurin HCI in Patients with Advanced or Metastatic Malignancies | 2009-07-29 | due-trials |
| Reported results | 2006-005118-11 | A Phase 2 Study of Pemetrexed versus Pemetrexed + Erlotinib in Second-Line Treatment in Patients with Nonsquamous NSCLC | 2010-10-14 | due-trials |
| Reported results | 2006-005305-58 | A Randomized, Double-Blind, Phase 2 Trial of Fulvestrant Plus Enzastaurin versus Fulvestrant Plus Placebo in Aromatase Inhibitor-Resistant Metastatic Breast Cancer | 2018-10-18 | due-trials |
| Reported results | 2006-005306-31 | Randomized, Double-Blind, Placebo-Controlled, Phase 2 Study of Gemcitabine and Cisplatin Plus Enzastaurin versus Gemcitabine and Cisplatin Plus Placebo, Followed by Maintenance Enzastaurin or Placebo ... | 2008-08-25 | due-trials |
| No trial status on register | 2006-005346-37 | A Randomized, Double-Blind, Placebo-Controlled Maintenance of Effect Study of Olanzapine in the Treatment of Disruptive Behavioral Symptoms in Children and Adolescents with Pervasive Developmental Dis... | bad-data | |
| Reported results | 2006-005383-51 | A Phase 3, Open-Label, Crossover Study to Evaluate the Efficacy and Safety of Human Insulin Inhalation Powder (HIIP) Compared with Once-Daily Insulin Glargine in Insulin-Naïve Patients with Type 2 Dia... | 2008-05-29 | due-trials |
| Listed as ongoing, but also has a completion date and reported results | 2006-005512-27 | A Randomized, Controlled, Open-Label Study of the Long-Term Impact on Functioning using Atomoxetine Hydrochloride Compared to Other Early Standard Care in the Treatment of Attention-Deficit/Hyperactiv... | 2009-10-07 | bad-data |
| Completed, but no date, and reported results | 2006-005971-17 | A Phase 2 Study of LY573636 as Treatment for Patients with Platinum-Resistant Ovarian Cancer Protocol H8K-MC-JZAG | bad-data | |
| Completed, but no date, and reported results | 2006-006043-32 | An open label pilot study on the tolerability of duloxetine in the treatment of depressed patients with Parkinson s disease | bad-data | |
| Reported results | 2006-006149-15 | An Exploratory Study of the Effect of Treatment Interruption on Safety of Exenatide in Patients with Type 2 Diabetes | 2008-04-29 | due-trials |
| Reported results | 2006-006315-68 | Comparison of the Effects of Teriparatide with those of Risedronate on Lumbar Spine Volumetric Bone Mineral Density in Glucocorticoid-Induced Osteoporosis in Men | 2010-10-06 | due-trials |
| Reported results | 2006-006375-21 | The COMPLETE T1D Trial: COMParison of Insulin Lispro Protamine Suspension and DETEmir in Type 1 Diabetes Comparison of Two Basal Insulin Analogs (Insulin Lispro Protamine Suspension and Insulin Detemi... | 2008-08-19 | due-trials |
| Reported results | 2006-006429-24 | Ensayo Fase II de Pemetrexed más Cisplatino como tratamiento de pacientes con cáncer microcítico de pulmón, enfermedad extendida | 2008-04-01 | due-trials |
| Reported results | 2006-006698-25 | A Phase 2 Double-Blind Randomized Study of Oral Enzastaurin HCl versus Placebo Concurrently with Pemetrexed (Alimta) as Second-Line Therapy in Patients with Advanced or Metastatic Non-Small Cell L... | 2008-10-01 | due-trials |
| Reported results | 2007-000281-21 | Enzastaurin (LY317615) Before and Concomitant with Radiation Therapy, Followed by Enzastaurin Maintenance Therapy in Patients with Newly Diagnosed Glioblastoma without Methylation of the Promoter Gene... | 2016-03-24 | due-trials |
| Reported results | 2007-000469-39 | An Open Label Follow-up Study of Patients Who Participated in Clinical Study B9R-HL-GDDV. A Phase IV, one-arm follow-up study to assess final adult results of GH treatment in patients with the Prader... | 2007-09-21 | due-trials |
| Reported results | 2007-000800-34 | A Multi-center, Inpatient, Phase 2, Double-blind, Placebo-controlled Dose Ranging Study of LY2140023 in Patients with DSM-IV Schizophrenia. | 2008-10-06 | due-trials |
| Reported results | 2007-000912-97 | Phase II Trial of Pemetrexed in Second Line Advanced/Metastatic Osteosarcomas | 2010-07-21 | due-trials |
| Reported results | 2007-000913-13 | Phase 2 Study of Concurrent Carboplatin, Pemetrexed, and Radiotherapy for Limited Stage Small Cell Lung Cancer | 2008-12-20 | due-trials |
| Reported results | 2007-001402-24 | Estudio fase II de LY573636 sódico administrado como tratamiento de segunda o tercera línea en pacientes con sarcoma de tejido blando irresecable o metastásico A Phase 2 Study of LY573636-sodium Admi... | 2010-02-10 | due-trials |
| Reported results | 2007-002150-39 | Estudio COMPLETE DT2: COMParación de una suspensión de insulina Lispro protamina y DETEmir en Diabetes mellitus Tipo 2 Comparación de dos análogos de insulina basal (suspensión de insulina Lispro pro... | 2008-09-26 | due-trials |
| Reported results | 2007-002418-20 | Estudio PERSISTENT: Estudio prospectivo y aleatorizado en el que se compara la suspensión de insulina lispro con protamina con la insulina glargina en pacientes con diabetes tipo 2 que reciben medicac... | 2008-10-03 | due-trials |
| Completed, but no date, and reported results | 2007-002691-33 | A Study to Assess the Effect of Exenatide Treatment on Mean 24-hour Heart Rate in Patients with Type 2 Diabetes | bad-data | |
| Reported results | 2007-002957-22 | Efficacy of once weekly exenatide long acting release and once daily insulin glargine in patients with Type 2 diabetes treated with metformin alone or in combination with sulphonylurea. | 2012-01-30 | due-trials |
| Not reported | 2007-003342-15 | A Randomized, Open-Label Study Comparing the Effectiveness of Olanzapine Pamoate Depot with Haloperidol Decanoate in the Treatment of Schizophrenia | 2008-06-13 | due-trials |
| Reported results | 2007-003844-31 | A Double-Blind, Randomized, Placebo-Controlled, Phase 2 Study of Enzastaurin with 5 FU/LV plus Bevacizumab as Maintenance Regimen Following First Line Therapy for Metastatic Colorectal Cancer | 2011-11-28 | due-trials |
| Reported results | 2007-003847-66 | Dose Finding and Randomized, Multicenter, Placebo- Controlled, Phase 2 Study of Enzastaurin and Sunitinib versus Placebo and Sunitinib in Patients with Metastatic Renal Cell Carcinoma | 2018-09-07 | due-trials |
| Reported results | 2007-003912-72 | A Randomized Phase 2 Study Comparing Erlotinib-Pemetrexed, Pemetrexed alone, and Erlotinib alone, as Second-Line Treatment for Non-Smoker Patients with Locally Advanced or Metastatic Non-Small Cell Lu... | 2012-01-05 | due-trials |
| Completed, but no date | 2007-004321-15 | A Randomized, Double-Blind, Placebo-Controlled, Parallel-Design, Multicenter Study to Evaluate the Urodynamic Effects of Tadalafil Once a Day for 12 Weeks in Men With Signs and Symptoms of Benign Pros... | bad-data | |
| Reported results | 2007-004864-29 | A Prospective Randomized Trial to Compare Basal Bolus therapies that use either Insulin Lispro Protamine Suspension or Insulin Glargine together with Lispro Insulin in Patients with Type 2 Diabetes | 2010-02-25 | due-trials |
| Reported results | 2007-004907-37 | A randomized phase 2 study of LY2181308 in combination with docetaxel versus docetaxel in hormone refractory prostate cancer | 2012-04-02 | due-trials |
| Reported results | 2007-004950-10 | Pemetrexed con suplemento simplificado de folato y dexametasona frente a pemetrexed con suplemento estándar como segunda línea de quimioterapia en pacientes con cáncer de pulmón no microcítico Pemet... | 2010-06-22 | due-trials |
| Reported results | 2007-005061-36 | Comparación de un régimen de insulina lispro premezclada (proporción baja, 25/75; y proporción media, 50/50) con un régimen de inyecciones separadas de insulina basal y en bolos, en pacientes con diab... | 2010-11-10 | due-trials |
| Reported results | 2007-005118-37 | Efecto de la inhibición de la γ-Secretasa sobre la progresión de la enfermedad de Alzheimer: LY450139 frente a placebo / Effect of γ-Secretase Inhibition on the Progression of Alzheimer’s Disease:... | 2011-04-12 | due-trials |
| Reported results | 2007-005210-39 | A Comparison of Prasugrel and Clopidogrel in Acute Coronary Syndrome (ACS) Subjects with Unstable Angina/Non-ST-Elevation Myocardial Infarction (UA/NSTEMI) Who are Medically Managed - The TRILOGY ACS ... | 2012-03-30 | due-trials |
| Reported results | 2007-005441-38 | Efficacy and Safety of Drotrecogin Alfa (Activated) in Adult Patients with Septic Shock | 2012-02-29 | due-trials |
| Reported results | 2007-006246-17 | A Phase 2 Study of Enzastaurin in Patients with Follicular Lymphoma | 2014-12-17 | due-trials |
| Reported results | 2007-007198-21 | A Phase 2/3, Placebo-Controlled, Efficacy and Safety Study of Once-Weekly, Subcutaneous LY2189265 Compared to Sitagliptin in Patients with Type 2 Diabetes Mellitus on Metformin | 2012-07-13 | due-trials |
| Reported results | 2007-007672-41 | Maintenance of Response After Open-Label Treatment with Atomoxetine Hydrochloride in Adult Outpatients with Attention-Deficit/Hyperactivity Disorder (ADHD): A Placebo-Controlled, Randomized Withdra... | 2013-10-02 | due-trials |
| Completed, but no date, and reported results Terminated | 2008-000191-24 | An Open Label Pilot Study of Atomoxetine Hydrochloride in Adolescents with Attentioin-Deficit/Hyperactivity Disorder and Comorbid Cannabis Abuse | bad-data | |
| Reported results | 2008-000748-14 | An Open Label, Multicenter Phase 2 Study of Single-Agent Enzastaurin HCl in Previously Treated Waldenstrom’s Macroglobulinemia or Multiple Myeloma | 2012-08-22 | due-trials |
| Reported results | 2008-000854-11 | Safety and Efficacy of Exenatide Once Weekly Injection versus Metformin, Dipeptidyl Peptidase-4 Inhibitor, or Thiazolidinedione as Monotherapy in Drug-Naive Patients with Type 2 Diabetes | 2010-06-09 | due-trials |
| Reported results | 2008-001055-21 | A Comparison of Psychosocial Outcomes Following Tadalafil Once a Day or PDE5 Inhibitor As Needed in Men With Erectile Dysfunction. | 2009-09-21 | due-trials |
| Reported results | 2008-001105-42 | A Phase 2 Study of Multiple Intravenous Doses of LY2127399, an Anti-BAFF Human Antibody, in Patients with Rheumatoid Arthritis on Concomitant Methotrexate and an Inadequate Response to TNFα Inhibitor ... | 2010-05-27 | due-trials |
| Reported results | 2008-001170-32 | Phase 3 Study of Pemetrexed, Cisplatin, and Radiotherapy Followed by Consolidation Pemetrexed versus Etoposide, Cisplatin, and Radiotherapy Followed by Consolidation Cytotoxic Chemotherapy of Choice i... | 2014-11-06 | due-trials |
| Reported results | 2008-001372-75 | Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of LY2245461 after Multiple Oral Administrations in Healthy Postmenopausal Women | 2010-08-06 | due-trials |
| Exempt | 2008-001535-35 | A Phase 1b/2 Study of Gemcitabine-Cisplatin, With or Without LY2275796 Sodium, in Patients with Advanced Stage IIIB or IV Non-Small Cell Lung Cancer | not-yet-due | |
| Reported results | 2008-001767-11 | A Randomized, Controlled, Open-Label Comparison Study of the Efficacy and Safety of Slow Transitioning compared with Fast Transitioning from a Stimulant Medication to Atomoxetine in Pediatric and Adol... | 2010-10-14 | due-trials |
| Ongoing | 2008-001829-33 | Duloxetine Versus Placebo in the Long-Term Treatment of Patients with Late-Life Major Depression | not-yet-due | |
| Reported results | 2008-002155-24 | A Phase 3, Double-Blind, Placebo-Controlled Study of Maintenance Pemetrexed plus Best Supportive Care versus Best Supportive Care Immediately Following Induction Treatment with Pemetrexed + Cisplatin ... | 2017-11-22 | due-trials |
| Reported results | 2008-002248-40 | Efecto de Duloxetina 60 mg, Administrado una Vez al Día, Frente a Placebo, en Pacientes con Lumbalgia Crónica Effect of Duloxetine 60 mg Once Daily versus Placebo in Patients with Chronic Low Back Pa... | 2009-07-06 | due-trials |
| Reported results | 2008-002319-42 | Comparación de dos estrategias de tratamiento diferentes en pacientes con trastorno depresivo mayor en tratamiento con escitalopram que no presentan mejoría: Estrategia de intervención temprana versus... | 2010-05-03 | due-trials |
| Completed, but no date, and reported results | 2008-002560-34 | A Randomized, Double-Blind, Placebo-Controlled Trial of the Efficacy and Safety of Duloxetine HCl in Patients with Central Neuropathic Pain Due to Multiple Sclerosis | bad-data | |
| Reported results | 2008-002693-35 | Comparison of the Effects of Teriparatide with those of Risedronate on Lumbar Spine Bone Mineral Density in Men and Postmenopausal Women with Low Bone Mass and a Recent Pertrochanteric Hip Fracture | 2015-10-20 | due-trials |
| Reported results | 2008-002758-39 | Effect of LY450139, a g-Secretase Inhibitor, on the Progression of Alzheimers Disease as Compared with Placebo. | 2011-07-11 | due-trials |
| Reported results | 2008-002841-21 | A Phase 3, Randomized, Double Blind, Placebo Controlled, Parallel Design, Multinational Study to Evaluate the Efficacy and Safety of Daily Tadalafil for 12 Weeks in Men with Signs and Symptoms of Beni... | 2009-11-09 | due-trials |
| Reported results | 2008-002857-18 | A Randomized, Double-Blind Comparison of LY2216684 and Placebo and Long Term Treatment with LY2216684 in Adult Patients with Major Depressive Disorder | 2011-03-02 | due-trials |
| Reported results | 2008-003843-36 | A Randomized Trial Comparing Exenatide with Placebo in Subjects with Type 2 Diabetes on Insulin Glargine With or Without Oral Antihyperglycemic Medications | 2010-01-04 | due-trials |
| Reported results | 2008-004207-63 | A 12-Week, Double-Blind, Placebo-Controlled Trial of LY2428757 in Patients with Type 2 Diabetes Mellitus | 2010-01-12 | due-trials |
| Reported results | 2008-004222-17 | A Randomized, Double-Blind, PLacebo-Controlled, Parallel Study to Assess the Efficacy and Safety of Tadalafil (LY450190) Once a Day in Subjects With Erectile Dysfunction Who Are Naive to PDE5 Inhibito... | 2010-01-15 | due-trials |
| Reported results | 2008-004330-24 | A Phase 2 Study of Pemetrexed and Cisplatin plus Cetuximab followed by Pemetrexed and Cetuximab Maintenance Therapy in Patients with Locally Advanced or Metastatic Non-Small Cell Lung Cancer (Stage II... | 2014-11-19 | due-trials |
| Reported results | 2008-004337-25 | A Randomized, Double-Blind, Placebo-Controlled, Parallel Design, Multinational Study to Evaluate the Efficacy and Safety of Tadalafil 2.5 and 5 mg Once Daily Dosing for 12 Weeks for the Treatment of E... | 2010-10-14 | due-trials |
| Reported results | 2008-004451-30 | A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Study with and without Enzastaurin in Combination with Docetaxel and Prednisone, Followed by Enzastaurin Maintenance as First-Line Treatment in... | 2010-06-03 | due-trials |
| Reported results | 2008-004875-23 | An Open-Label Extension Study of Multiple Subcutaneous Doses of LY2127399, an Anti-BAFF Human Antibody, in Patients with Rheumatoid Arthritis | 2012-01-13 | due-trials |
| Reported results | 2008-004894-16 | Phase 2, Dose-Ranging Study of Multiple Subcutaneous Doses of LY2127399, an Anti-BAFF Human Antibody, in Patients with Active Rheumatoid Arthritis Despite Ongoing Methotrexate Therapy | 2010-12-17 | due-trials |
| Reported results Terminated | 2008-004997-41 | Effectiveness of Prasugrel versus Clopidogrel in Subjects with High Platelet Reactivity on Clopidogrel Following Elective Percutaneous Coronary Intervention with Implantation of Drug-Eluting Stent | 2011-03-18 | due-trials |
| Reported results | 2008-005128-10 | Assessment of Dose-Dependent Effects of LY2189265 on Glycemic Control in Patients with Type 2 Diabetes Treated only with Lifestyle Interventions | 2010-01-25 | due-trials |
| Completed, but no date Terminated | 2008-005496-10 | An Open-label, Randomized, Phase 2 Study of R-CHOP Plus Enzastaurin versus R-CHOP in the First-Line Treatment of Patients with Intermediate and High-Risk Diffuse Large B-Cell Lymphoma | bad-data | |
| Ongoing | 2008-005695-27 | Comparing Problem Solving Treatment combined with duloxetine with Problem Solving Treatment alone for patients with major depressive disorder in primary care | not-yet-due | |
| Reported results | 2008-006209-17 | A Phase 1/Randomized Phase 2 Study to Evaluate LY2603618 in Combination with Gemcitabine in Patients with Pancreatic Cancer Studio di fase 1/fase 2 randomizzato per la valutazione di LY2603618 in c... | 2013-12-09 | due-trials |
| Reported results | 2008-006317-25 | A Comparison of Adding Exenatide with Switching to Exenatide in Patients with Type 2 Diabetes Experiencing Inadequate Glycemic Control with Sitagliptin plus Metformin | 2010-04-12 | due-trials |
| Reported results | 2008-006492-71 | A double-blind, efficacy and safety study of duloxetine versus placebo in the treatment of children and adolescents with major depressive disorder | 2011-10-13 | due-trials |
| Reported results | 2008-006709-18 | An exploratory, prospective phase II study to investigate progression-free survival, response and overall survival seen with pemetrexed/cisplatin and the role of thymidylate synthase expression. | 2011-06-10 | due-trials |
| Reported results | 2008-006732-35 | A Single-Arm, Phase 2 Trial of Pemetrexed, Cisplatin, and Bevacizumab as Induction, Followed by Pemetrexed and Bevacizumab as Maintenance, in First-Line Treatment of Nonsquamous Advanced NSCLC | 2013-12-06 | due-trials |
| Reported results | 2008-007307-91 | A Long-Term, Phase 2, Multicenter, Randomized, Open-Label, Comparative Safety Study of LY2140023 Versus Atypical Antipsychotic Standard of Care in Patients with DSM-IV-TR Schizophrenia | 2010-12-21 | due-trials |
| Reported results | 2008-007459-28 | Multiple Subcutaneous Doses of LY2127399, an Anti-BAFF Human Antibody, in Subjects with Relapsing-Remitting Multiple Sclerosis | 2012-06-13 | due-trials |
| Reported results | 2008-007769-21 | A Randomized, Open-label Study on the Effects of Insulin Pen Devices on Glycemic Control in Children, Adolescents and Adults with Type 1 Diabetes: Novel Pen with Memory Function (HumaPen® Memoir) vs. ... | 2011-07-14 | due-trials |
| Reported results | 2008-007926-21 | Effect of Passive Immunization on the Progression of Alzheimer`s Disease: LY2062430 versus Placebo | 2012-08-20 | due-trials |
| Reported results | 2009-009500-39 | A Randomized Trial Comparing either Basal Insulin/Glargine, Exenatide and Metformin Therapy (BET) or Basal Insulin/Glargine, Bolus Insulin Lispro and Metformin Therapy (BBT) in Subjects with Type 2 D... | 2012-08-20 | due-trials |
| Completed, but no date, and reported results | 2009-009696-34 | A Phase 2 Dose-Ranging Study of Multiple Subcutaneous Doses of LY2439821 (an Anti-IL-17 Antibody) in Patients with Active Rheumatoid Arthritis on Concomitant DMARD Therapy | bad-data | |
| Reported results | 2009-010008-27 | Duloxetine 60 mg Once Daily Versus Placebo in the Treatment of Patients with Osteoarthritis Knee Pain Duloxetina 60 mg, Administrado una Vez al Día, Frente a Placebo en el Tratamiento de Pacientes co... | 2010-05-20 | due-trials |
| Reported results | 2009-010063-16 | Use of Duloxetine or Pregabalin in Monotherapy versus Combination Therapy of Both Drugs in Patients with Painful Diabetic Neuropathy The COMBO (COmbination vs Monotherapy of pregaBalin and dulOxetine... | 2011-11-11 | due-trials |
| Ongoing | 2009-010188-18 | Effectiveness of Transmural Collaborative care and Duloxetine for major depressive disorder and (sub)chronic pain: a randomized placebo-controlled Multi-Centre trial. | not-yet-due | |
| Reported results | 2009-010276-16 | A Long-Term, Open-Label, Safety Study of Oral Olanzapine in Adolescents with Bipolar I Disorder (Manic or Mixed Episodes) or Schizophrenia | 2013-05-07 | due-trials |
| Reported results | 2009-010739-42 | A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Parallel-Design, Global Multicenter Study to Evaluate the Efficacy and Safety of Tadalafil Once Daily Dosing for 12 Weeks in Men with Signs and... | 2011-01-27 | due-trials |
| Reported results | 2009-010830-23 | Efficacy of Once-Weekly Exenatide versus Once or Twice Daily Insulin Detemir in Patients with Type 2 Diabetes Treated with Metformin Alone or in Combination with Sulphonylurea | 2011-12-29 | due-trials |
| Reported results | 2009-010902-13 | Duloxetina versus placebo en el tratamiento de pacientes de avanzada edad con trastorno de ansiedad generalizada Duloxetine versus Placebo in the Treatment of Elderly Patients with Generalized Anxiet... | 2012-07-21 | due-trials |
| Reported results | 2009-011318-22 | Efectos de la administración de tadalafilo (LY450190) una vez al día o a demanda en comparación con la administración de citrato de sildenafilo a demanda sobre la discontinuación del tratamiento en pa... | 2011-06-15 | due-trials |
| Reported results | 2009-011426-33 | Assessing the Effect of Missing Doses (Off-Days) of Daily Medication in Patients Stable on Pharmacotherapy for ADHD Receiving Atomoxetine or OROS Methylphenidate: A Parallel Matched Group Clinical Stu... | 2011-05-03 | due-trials |
| Reported results | 2009-011611-21 | Phase 2 Study of Pemetrexed in Combination with Cisplatin and Cetuximab in Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck | 2012-10-31 | due-trials |
| Reported results | 2009-011739-11 | Estudio fase 2 de Pemetrexed y Cisplatino como tratamiento de inducción, seguido de Pemetrexed y Cisplatino en combinación con radioterapia, en pacientes con cáncer de pulmón no microcítico, localment... | 2013-07-23 | due-trials |
| Reported results | 2009-011837-29 | A Phase 4, 8-week, double-blind, randomized study comparing switching to duloxetine or escitalopram in patients with major depressive disorder and residual apathy in the absence of depressed mood. | 2010-12-17 | due-trials |
| Reported results | 2009-011850-17 | A Randomised, Double-Blind, Placebo-Controlled Study to Evaluate the Effect on Unassisted Erectile Function of the Early Use of Tadalafil 5 mg Once a Day and Tadalafil 20 mg On Demand Treatment for 9 ... | 2013-01-18 | due-trials |
| Reported results | 2009-011883-12 | A Phase 2 Study for Transdermal Application of Teriparatide | 2011-09-06 | due-trials |
| Reported results | 2009-012011-17 | Safety and Efficacy of Exenatide Once Weekly versus Liraglutide in Subjects with Type 2 Diabetes and Inadequate Glycemic Control Treated with Lifestyle Modification and Oral Antidiabetic Medications | 2011-04-07 | due-trials |
| Reported results | 2009-013420-23 | Neurobiological Correlates of Antidepressant Response After Duloxetine Hydrochloride Treatment in Subjects with Major Depressive Disorder | 2013-03-05 | due-trials |
| Reported results | 2009-013787-39 | A Phase 2 Study to Evaluate LY2603618 in Combination with Pemetrexed in Patients with Advanced or Metastatic Non-small Cell Lung Cancer | 2015-12-03 | due-trials |
| Listed as ongoing, but also has a completion date | 2009-013838-25 | "Estudio en fase 3 aleatorizado, multicéntrico y abierto de quimioterapia con gemcitabina-cisplatino más IMC-11F8 en comparación con quimioterapia con gemcitabina-cisplatino sola en el tratamiento de ... | 2024-05-03 | bad-data |
| Reported results | 2009-014176-22 | A Comparison of Prasugrel at the Time of Percutaneous Coronary Intervention (PCI) Or as Pre-treatment At the Time of Diagnosis in Patients with Non-ST-Elevation Myocardial Infarction (NSTEMI) - The ... | 2013-02-18 | due-trials |
| Reported results | 2009-014424-29 | Estudio de extensión abierto para pacientes con enfermedad de Alzheimer que hayan completado uno de los dos estudios fase 3 doble ciego con Semagacestat (H6L-MC-LFAN o H6L-MC-LFBC). Open-Label Exten... | 2011-04-15 | due-trials |
| Reported results | 2009-014591-21 | A Randomized Phase 3 Study of Tasisulam Administered as an Intravenous Infusion on Day 1 of a 28-Day Cycle vs. Paclitaxel as Second-Line Treatment in Patients with Metastatic Melanoma. | 2011-03-18 | due-trials |
| Reported results | 2009-014605-14 | A Phase 4, 8-Week, Double-Blind, Randomized, Placebo-Controlled Study Evaluating the Efficacy of Duloxetine 60 mg Once Daily in Outpatients with Major Depressive Disorder and Associated Painful Physic... | 2010-10-26 | due-trials |
| Reported results | 2009-014739-19 | A Phase 2 Study of LY2605541 Compared with Insulin Glargine in the Treatment of Type 2 Diabetes Mellitus | 2011-01-10 | due-trials |
| Reported results | 2009-014803-30 | A Randomized, Open-Label, Parallel-Arm, Noninferiority Comparison of the Effects of Two Doses of LY2189265 and Insulin Glargine on Glycemic Control in Patients with Type 2 Diabetes on Stable Doses of ... | 2012-11-23 | due-trials |
| Reported results | 2009-014841-10 | Impacto de LY2189265 en comparación con el de metformina en el control glucémico en la Diabetes Mellitus de Tipo 2 Inicial (AWARD-3: Evaluación de la Administración Semanal de LY2189265 en Diabetes ... | 2012-07-19 | due-trials |
| Reported results | 2009-014958-16 | A 12-Week, Phase 2, Randomized, Double-Blind, Placebo-Controlled Study of LY2599506 in Patients with Type 2 Diabetes Mellitus Treated with Diet and Exercise, with or without Metformin Estudio de fase ... | 2010-07-01 | due-trials |
| Reported results | 2009-016007-39 | A 12-Week, Phase 2, Randomized, Double-Blind, Active-Controlled Study of LY2599506 Given as Monotherapy or in Combination with Metformin in Patients with Type 2 Diabetes Mellitus | 2010-06-14 | due-trials |
| Reported results | 2009-016245-26 | Estudio de Fase 2, de 17 Semanas, Multicéntrico, Aleatorizado y Doble Ciego, Sobre la Eficacia de LY2140023 Combinado con Tratamiento Clínico Habitual Comparado con Placebo Combinado con Tratamiento C... | 2012-06-28 | due-trials |
| Reported results | 2009-016800-22 | A Phase 2 Clinical Study to Evaluate Daily Oral Doses of LY500307 for 24 weeks in Men with Lower Urinary Tract Symptoms (LUTS) and Prostatic Enlargement Secondary to Benign Prostatic Hyperplasia (BPH) | 2011-10-18 | due-trials |
| Reported results | 2009-017479-29 | A Phase 2 Efficacy and Safety Study of LY2484595 Alone and in Combination with Atorvastatin, Simvastatin, and Rosuvastatin in Patients with Hypercholesterolemia or Low HDL-C | 2011-06-28 | due-trials |
| Reported results | 2009-017591-24 | A Randomized Phase 2 Study of LY2181308 in Combination with Docetaxel versus Docetaxel in Patients with Locally Advanced or Metastatic Non-Small Cell Lung Cancer who Were Previously Treated with Fir... | 2012-06-29 | due-trials |
| Reported results | 2009-017852-28 | A Phase 2, Multicenter, Double-Blind, Placebo-Controlled Comparator Study of 2 Doses of LY2140023 versus Placebo in Patients with DSM-IVTR Schizophrenia | 2012-05-24 | due-trials |
| Reported results | 2009-017853-36 | A Long-Term, Open-Label, Multicenter Study of LY2140023 Compared to Atypical Antipsychotic Standard of Care in Patients with DSM-IV-TR Schizophrenia | 2012-10-10 | due-trials |
| Reported results | 2009-018148-45 | An exploratory Phase 2 study of Pemetrexed and Cisplatin as Preoperative chemotherapy in the treatment of Stage IIIAN2 nonsquamous non-Small cell lung cancer | 2016-04-05 | due-trials |
| Reported results | 2010-018664-16 | A Double-Blind, Randomized, Crossover Trial of CSII Reservoir In-use Comparing Insulin Lispro Formulation to Insulin Aspart in Patients with Type 1 Diabetes Mellitus | 2011-12-07 | due-trials |
| Reported results | 2010-018759-82 | The Effect of Postprandial Hyperglycemia on Arterial Stiffness in Patients with Type 2 Diabetes | 2013-02-28 | due-trials |
| Reported results | 2010-018948-14 | A Dose-Ranging And Efficacy Study of LY2439821 (an Anti-IL-17 Antibody) in Patients With Moderate-To-Severe Psoriasis | 2016-08-02 | due-trials |
| Reported results | 2010-019223-55 | Comparación del efecto de LY2189265 frente a insulina glargina, administrados en combinación con insulina lispro, para el tratamiento hasta alcanzar el objetivo, en pacientes con diabetes mellitus tip... | 2012-09-21 | due-trials |
| Reported results | 2010-019581-82 | The Effect of LY2189265 on Blood Pressure and Heart Rate, as Assessed by Ambulatory Blood Pressure Monitoring, in Patients with Type 2 Diabetes Mellitus | 2012-01-04 | due-trials |
| Reported results | 2010-019724-30 | Comparación de insulina lispro premezclada (proporción baja) dos veces al día frente a insulina glargina una vez al día e insulina lispro prandial una vez al día, como estrategias de intensificación d... | 2012-11-14 | due-trials |
| Reported results | 2010-019758-42 | A Phase 2 Randomized Study of LY2541546 Versus Placebo in Postmenopausal Women with Low Bone Mineral Density: An Evaluation of the Dose Response Relationship using Bone Mineral Density | 2013-02-22 | due-trials |
| Reported results | 2010-020220-22 | A Randomized, Double-Blind, Placebo Controlled Study to Evaluate the Effect of Tadalafil Once Daily for 8 Weeks on Prostatic Blood Flow and Perfusion Parameters in Men with Signs and Symptoms of Benig... | 2012-09-25 | due-trials |
| Completed, but no date, and reported results Terminated | 2010-020404-29 | A Randomized, Double-Masked, Placebo-Controlled, Multicenter, Phase 2 Study to Evaluate the Safety and Renal Efficacy of LY2382770 in Patients with Diabetic Kidney Disease due to Type 1 or Type 2 Diab... | bad-data | |
| Exempt, with results | 2010-020408-31 | A Phase 1/Randomized Phase 2 Study to Evaluate LY2603618 in Combination with Pemetrexed and Cisplatin in Patients with Stage IV Non-small Cell Lung Cancer | 2014-09-04 | not-yet-due |
| Reported results | 2010-020604-29 | A Phase 3b, randomized, double-blind, placebo-controlled parallel-design study to evaluate the efficacy and safety of tadalafil co-administered with finasteride for 6 months in men with lower urinary ... | 2012-05-24 | due-trials |
| Reported results | 2010-020726-18 | Estudio Abierto de Seguridad a Largo Plazo de LY2216684 12 a 18 mg Una Vez al Día como Tratamiento Adyuvante para Pacientes con Trastorno Depresivo Mayor con Respuesta Parcial al Tratamiento con un In... | 2012-12-27 | due-trials |
| Reported results | 2010-021037-32 | A Randomized, Double-Blind, Multicenter Phase 3 Study of Irinotecan, Folinic Acid, and 5-Fluorouracil (FOLFIRI) Plus Ramucirumab or Placebo in Patients With Metastatic Colorectal Carcinoma Progressive... | 2016-08-01 | due-trials |
| Reported results | 2010-021069-63 | A Randomized, Placebo Controlled Clinical Trial to Evaluate Cardiovascular Outcomes after Treatment with exenatide once weekly in Patients with Type 2 Diabetes Mellitus” (EXSCEL: EXenatide Study of ... | 2017-04-24 | due-trials |
| Reported results | 2010-021155-11 | Continued Efficacy and Safety Monitoring of Solanezumab, an Anti-Amyloid B Antibody in Patients with Alzheimer's Disease. Monitorización continua de la eficacia y la seguridad de solanezumab, un antic... | 2017-02-17 | due-trials |
| Reported results | 2010-021214-39 | A Randomized, Placebo-controlled, Double-blind Study of LY2216684 Fixed-dose 12 mg and 18 mg Once Daily as Adjunctive Treatment for Patients With Major Depressive Disorder Who Are Partial Responders t... | 2013-10-07 | due-trials |
| Reported results | 2010-021215-16 | A Randomized, Placebo-Controlled, Double-Blind Study of LY2216684 Flexible-Dose 12 mg to 18 mg Once Daily and LY2216684 Fixed-Dose 6 mg Once Daily as Adjunctive Treatment for Patients with Major Depre... | 2013-08-13 | due-trials |
| Reported results | 2010-021216-41 | A Randomized Placebo-Controlled, Double-Blind Study of LY2216684 Flexible-Dose 12 to 18 mg Once Daily as Adjunctive Treatment for Patients with Major Depressive Disorder Who Are Partial Responders to ... | 2013-04-30 | due-trials |
| Reported results | 2010-021297-11 | A Randomized, Double-Blind, Phase 3 Study of Docetaxel and Ramucirumab versus Docetaxel and Placebo in the Treatment of Stage IV Non-Small Cell Lung Cancer Following Disease Progression after One Pri... | 2016-08-10 | due-trials |
| Reported results | 2010-021395-28 | Effect of Teriparatide on Femoral Neck Fracture Healing | 2014-02-04 | due-trials |
| Reported results | 2010-021516-42 | Two Approaches to Escalate Lispro Therapy in Patients with Type 2 Diabetes Mellitus Not Achieving Adequate Glycemic Control on Basal Insulin Therapy and Oral Agents Alone | 2013-01-14 | due-trials |
| Reported results | 2010-022099-29 | A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Subcutaneous LY2127399 in Patients with Systemic Lupus Erythematosus (SLE) (ILLUMINATE... | 2014-12-10 | due-trials |
| Reported results | 2010-022100-42 | A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Subcutaneous LY2127399 in Patients with Systemic Lupus Erythematosus (SLE) (ILLUMINATE... | 2014-12-10 | due-trials |
| Reported results | 2010-022101-18 | A Phase 3b, Multicenter, Open-Label Study to Evaluate the Long-Term Safety and Efficacy of Subcutaneous LY2127399 in Patients with Systemic Lupus Erythematosus (SLE) (ILLUMINATE-X) Studio di fase... | 2015-01-12 | due-trials |
| Exempt, with results | 2010-022160-13 | Phase 1b/2a Study Combining LY2157299 with Standard Temozolomide-based Radiochemotherapy in Patients with Newly Diagnosed Malignant Glioma | 2016-11-23 | not-yet-due |
| Reported results | 2010-022205-17 | A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of LY2127399 in Patients with Moderate to Severe Rheumatoid Arthritis (RA) who had an Ina... | 2014-01-21 | due-trials |
| Reported results | 2010-022206-40 | A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Safety and Efficacy of LY2127399 in Patients with Rheumatoid Arthritis (RA) with or without Background Diseas... | 2013-07-23 | due-trials |
| Reported results | 2010-022207-22 | A Phase 3, Multicenter, Randomized, Double Blind, Placebo Controlled Study to Evaluate the Efficacy and Safety of LY2127399 in Patients with Moderate to Severe Rheumatoid Arthritis (RA) who had an Ina... | 2014-01-06 | due-trials |
| Reported results | 2010-022208-36 | A Phase 3b, Multicenter, Open-Label Study to Evaluate the Long-Term Safety and Efficacy of LY2127399 in Patients with Rheumatoid Arthritis (RA) | 2014-03-24 | due-trials |
| Reported results | 2010-022338-10 | Phase 2 Study of LY2157299 in Patients with Hepatocellular Carcinoma | 2019-12-24 | due-trials |
| Reported results | 2010-022504-42 | A Randomized, Double-Blind, Placebo-Controlled, Dose-Ranging, Parallel-Group, Phase 2b Study of LY3009104 in Patients with Active Rheumatoid Arthritis on background Methotrexate Therapy | 2014-03-31 | due-trials |
| Ongoing | 2010-022674-14 | Estudio en fase 2, abierto, multicéntrico y aleatorizado para evaluar la seguridad y la eficacia de cisplatino y pemetrexed con o sin cixutumumab como tratamiento de primera línea en pacientes con car... | not-yet-due | |
| Reported results | 2010-023231-42 | A Randomized, Double-Blind, Placebo-Controlled, Phase 2b Study of LY2409021 in Patients with Type 2 Diabetes Mellitus | 2012-03-19 | due-trials |
| Reported results | 2010-023550-36 | A Phase 3, Multicenter, Double-Blind Comparison of LY2140023 and Aripiprazole in Patients with DSM-IV-TR Schizophrenia Followed by Open-Label Treatment with LY2140023 | 2012-10-12 | due-trials |
| Reported results | 2010-023799-21 | The Effect of Dulaglutide on Major Cardiovascular Events in Patients with Type 2 Diabetes: Researching Cardiovascular Events with a Weekly INcretin in Diabetes (REWIND) | 2018-08-21 | due-trials |
| Reported results | 2010-024014-60 | An Open-Label, Multicenter, Randomized, Phase 2 Study Evaluating the Safety and Efficacy of Cisplatin and Pemetrexed with or without Cixutumumab as First-Line Therapy in Patients with Advanced Nonsqua... | 2016-06-10 | due-trials |
| Reported results | 2010-024320-23 | A Proof-of-Concept Study of the Effects of LY2828360 in the Treatment of Patients with Osteoarthritic Knee Pain | 2011-09-13 | due-trials |
| Reported results | 2010-024632-42 | LY2216684 Compared to Placebo as Adjunctive Therapy to SSRI in the Prevention of Symptom Reemergence in Major Depressive Disorder LY2216684 comparado frente a placebo como tratamiento combinado con... | 2013-11-14 | due-trials |
| Reported results | 2011-000211-64 | A Phase 1b/2 Study with Gemcitabine and LY2157299 for Patients with Metastatic Cancer (Phase 1b) and Advanced or Metastatic Unresectable Pancreatic Cancer (Phase 2) Studio di fase 1b/2 sull'ÃÂuso... | 2016-12-26 | due-trials |
| Reported results | 2011-000426-29 | A Phase 2 Randomized Study to Investigate the Efficacy and Safety of LY2495655 Versus Placebo in Older Patients Undergoing Elective Total Hip Arthroplasty (eTHA) | 2014-02-19 | due-trials |
| Reported results | 2011-000828-15 | A ProspEctive, Randomized, DoubLE-Blind CoMparison of a Long-Acting Basal Insulin Analog LY2963016 to Lantus® in Adult PatiENTs with Type 2 Diabetes Mellitus: The ELEMENT 2 Study Estudio prospectiv... | 2012-09-18 | due-trials |
| Reported results | 2011-000829-73 | A Prospective, Randomized, Open-Label Comparison of a Long-Acting Basal Insulin Analog LY2963016 to Lantus® in Combination with Mealtime Insulin Lispro in Adult Patients with Type 1 Diabetes Mellitus | 2013-03-25 | due-trials |
| Reported results | 2011-000841-19 | Home Delivery of Pemetrexed as Maintenance Treatment in Patients Who Have Not Progressed after Induction Therapy for Advanced Nonsquamous Nonsmall Cell Lung Cancer: A Feasibility Study | 2013-09-23 | due-trials |
| Reported results | 2011-000842-39 | A Comparison of LY2605541 versus Insulin Glargine as Basal Insulin Treatment in Combination with Oral Anti-Hyperglycemia Medications in Insulin-Naïve Patients with Type 2 Diabetes Mellitus: A Doub... | 2014-01-24 | due-trials |
| Ongoing | 2011-001012-56 | A Phase 2 Study of LY2784544 in Patients with Myeloproliferative Neoplasms | not-yet-due | |
| Reported results | 2011-001116-65 | Second study of the Effect of Teriparatide on Femoral Neck Fracture Healing | 2013-12-04 | due-trials |
| Reported results | 2011-001253-82 | Protocol I2R-MC-BIAO The Impact of LY2605541 versus Insulin Glargine for Patients with Type 1 Diabetes Mellitus Treated with Preprandial Insulin Lispro: a Double-Blind, Randomized, 52 Week Study The ... | 2014-02-03 | due-trials |
| Reported results | 2011-001254-29 | Protocol I2R-MC-BIAM The Impact of LY2605541 versus Insulin Glargine for Patients with Type 2 Diabetes Mellitus Advanced to Multiple Injection Bolus Insulin with Insulin Lispro: a Double-Blind, Rando... | 2013-08-13 | due-trials |
| Reported results | 2011-001261-40 | Protocol I2R-MC-BIAN (a) Study: The Impact of LY2605541 versus Insulin Glargine for Patients with Type 1 Diabetes Mellitus Treated with Preprandial Insulin Lispro: an Open-Label, Randomized, 78 week ... | 2014-06-07 | due-trials |
| Reported results | 2011-001873-24 | A multiple ascending dose study of Tadalafil to assess the pharmacokinetics and safety in a pediatric population with Pulmonary Arterial Hypertension | 2019-04-03 | due-trials |
| Reported results | 2011-002292-41 | A Phase 3, Short-Term, Multicenter, Placebo-Controlled, Randomized Withdrawal Study of LY2140023 Monohydrate in Patients with DSM-IV-TR Schizophrenia | 2012-09-18 | due-trials |
| Listed as ongoing, but also has a completion date | 2011-002325-22 | A Multicenter, Randomized, Double-Blind, Active and Placebo-Controlled 16-Week Study Followed by Long-Term Evaluation of Efficacy and Safety of Ixekizumab (LY2439821) in Patients with Active Ankylosin... | 2013-12-15 | bad-data |
| Reported results | 2011-002326-49 | A Multicenter, Randomized, Double-Blind, Active and Placebo-Controlled 24-Week Study Followed by Long-Term Evaluation of Efficacy and Safety of Ixekizumab (LY2439821) in Biologic Disease-Modifying Ant... | 2017-09-22 | due-trials |
| Reported results | 2011-002328-42 | Protocol I1F-MC-RHBE A Multicenter, Randomized, Double-Blind, Placebo-Controlled 24-Week Study Followed by Long-Term Evaluation of Efficacy and Safety of Ixekizumab (LY2439821) in Biologic Disease-Mod... | 2019-06-26 | due-trials |
| Reported results | 2011-002970-22 | A Multicenter Study with a Randomized, Double-Blind, Placebo-Controlled Induction Dosing Period Followed by a Randomized Maintenance Dosing Period and a Long- Term Extension Period to Evaluate the Eff... | 2018-09-20 | due-trials |
| Reported results | 2011-003810-18 | A Randomized, Open-Label, Parallel-Arm Study Comparing the Effect of Once-Weekly Dulaglutide with Once-Daily Liraglutide in Patients with Type 2 Diabetes (AWARD-6: Assessment of Weekly AdministRation ... | 2013-11-25 | due-trials |
| Reported results | 2011-003822-29 | A Randomized Phase 2 Placebo-Controlled Study of LY2495655 in Patients with Advanced or Metastatic Pancreatic Cancer Receiving Chemotherapy | 2016-02-04 | due-trials |
| Reported results | 2011-004327-13 | Long-Term Open-Label Safety Study of LY2140023 in Patients with Schizophrenia | 2012-10-19 | due-trials |
| Reported results | 2011-004350-26 | A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study Comparing the Efficacy and Safety of LY2439821 to Etanercept and Placebo in Patients with Moderate-to-Severe Plaque Psoriasis | 2019-07-18 | due-trials |
| Reported results | 2011-004368-31 | A 12-Week Multicenter, Randomized, Double-Blind, Placebo Controlled Study Comparing the Efficacy and Safety of LY2439821 to Etanercept and Placebo in Patients with Moderate to Severe Plaque Psoriasis ... | 2019-07-30 | due-trials |
| Listed as ongoing, but also has a completion date | 2011-004418-40 | A Phase 2 Study of LY2157299 Monohydrate Monotherapy or LY2157299 Monohydrate plus Lomustine Therapy compared to Lomustine Monotherapy in Patients with Recurrent Glioblastoma | 2024-10-10 | bad-data |
| Reported results | 2011-005103-32 | A Multicenter, Randomized, Double-Blind, Placebo Controlled Phase 2 Study of LY2127399 in Combination with Bortezomib and Dexamethasone in Patients with Previously Treated Multiple Myeloma | 2014-10-28 | due-trials |
| Exempt, with results | 2011-005197-40 | A Randomized, Double-Blind, Placebo-Controlled Phase 1b/2 Study of LY2228820, a p38MAPK Inhibitor, plus Gemcitabine and Carboplatin versus Gemcitabine and Carboplatin for Women with Platinum-Sensitive... | 2018-05-11 | not-yet-due |
| Reported results Terminated | 2011-005217-37 | Assessment of Safety, Tolerability, and Pharmacodynamic Effects of LY2886721 in Patients with Mild Cognitive Impairment Due to Alzheimer's Disease or Mild Alzheimer's Disease Valutazione della sicu... | 2013-06-13 | due-trials |
| Reported results | 2011-005866-39 | A Comparison of LY2605541 versus Insulin Glargine Alone or in Combination with Pre study Oral Antihyperglycemic Medications in Patients with Type 2 Diabetes Mellitus Previously Treated with Basal Insu... | 2013-12-17 | due-trials |
| Reported results | 2011-006062-40 | A Phase 2 Randomized Study to Investigate the Efficacy and Safety of LY2495655 Versus Placebo in Older Patients Who Have Fallen Recently and Have Muscle Weakness | 2013-12-13 | due-trials |
| Reported results | 2012-000061-21 | Protocol I1V-MC-EIAN Assessment of Clinical Effects of Cholesteryl Ester Transfer Protein Inhibition with Evacetrapib in Patients at a High-Risk for Vascular Outcomes - the ACCELERATE Study Valuta... | 2016-07-19 | due-trials |
| Reported results | 2012-000123-41 | Teriparatide and Risedronate in the Treatment of Patients with Severe Postmenopausal Osteoporosis: Comparative Effects on Vertebral Fractures | 2016-07-14 | due-trials |
| Reported results Terminated | 2012-000773-23 | Study of the Safety and Efficacy of LY2623091 in Chronic Kidney Disease Patients | 2013-03-20 | due-trials |
| Reported results | 2012-000829-44 | A Randomized, Open-Label, Parallel-Arm Study Comparing the Effect of Once-Weekly Dulaglutide with Insulin Glargine on Glycemic Control in Patients with Type 2 Diabetes and Moderate or Severe Chronic K... | 2016-12-20 | due-trials |
| Reported results Terminated | 2012-001618-40 | Pharmacokinetic Evaluations of Tabalumab Following Subcutaneous Administration by Prefilled syringe or Auto-Injector in Patients with Rheumatoid Arthritis Who Have Had an Inadequate Response to Methot... | 2013-02-07 | due-trials |
| Reported results | 2012-002322-73 | A Randomized, Double-Blind, Placebo- and Active Controlled, Phase 3 Study Evaluating the Efficacy and Safety of Baricitinib in Patients with Moderately to Severely Active Rheumatoid Arthritis Who Have... | 2017-01-10 | due-trials |
| Reported results | 2012-002323-15 | A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study Evaluating the Efficacy and Safety of Baricitinib (LY3009104) in Patients with Moderately to Severely Active Rheumatoid Arthritis Who Have... | 2014-11-04 | due-trials |
| Reported results | 2012-002324-32 | A Randomized, Double-Blind, Active-Controlled, Phase 3 Study to Evaluate the Efficacy and Safety of Baricitinib (LY3009104) in Patients with Moderately to Severely Active Rheumatoid Arthritis Who Have... | 2015-10-22 | due-trials |
| Reported results | 2012-002339-27 | A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study to Evaluate the Efficacy and Safety of Baricitinib (LY3009104) in Patients with Inadequate Response to Conventional Disease-Modifying Anti... | 2015-01-07 | due-trials |
| Listed as ongoing, but also has a completion date and reported results | 2012-002354-23 | A Double-Blind Efficacy and Safety Study of the Phosphodiesterase Type 5 Inhibitor Tadalafil in Pediatric Patients with Pulmonary Arterial Hypertension | 2021-03-10 | bad-data |
| Reported results | 2012-002911-24 | Protocol H9X-MC-GBDG A Randomized, Parallel-Arm, Double-Blinded Study Comparing the Effect of Once-Weekly Dulaglutide with Placebo in Patients with Type 2 Diabetes Mellitus on Sulfonylurea Therapy (AW... | 2014-12-02 | due-trials |
| Reported results | 2012-003174-83 | A Phase 1b/2 Double-Blind Randomized Trial of the Hedgehog/SMO Antagonist LY2940680 in Combination with Carboplatin and Etoposide Followed by LY2940680 versus Carboplatin and Etoposide Plus Placebo Fo... | 2015-02-09 | due-trials |
| Reported results | 2012-003201-96 | A Single-Arm, Multicenter, Open-Label, Phase 2 Study of Gemcitabine-Cisplatin Chemotherapy Plus Necitumumab (IMC-11F8) in the First-Line Treatment of Patients With Stage IV Squamous Non-Small Cell Lun... | 2015-12-03 | due-trials |
| Reported results | 2012-003214-13 | A Randomized, Multicenter, Open-Label, Phase 2 Study of Paclitaxel-Carboplatin Chemotherapy Plus Necitumumab (IMC-11F8) Versus Paclitaxel-Carboplatin Chemotherapy Alone in the First-Line Treatment of ... | 2017-07-14 | due-trials |
| Reported results | 2012-003686-17 | A Phase 3, Multicenter Study to Evaluate the Long-Term Safety and Efficacy of Baricitinib in Patients with Rheumatoid Arthritis | 2020-11-12 | due-trials |
| Listed as ongoing, but also has a completion date and reported results | 2012-003837-41 | A Phase 3, Double-Blind, Randomized, Efficacy and Safety Comparison of Prasugrel and Placebo in Pediatric Patients with Sickle Cell Disease | 2015-09-16 | bad-data |
| Reported results | 2012-003941-13 | A Comparison of LY2605541 versus Human Insulin NPH as Basal Insulin Treatment in Insulin-Naïve Patients with Type 2 Diabetes Mellitus not Adequately Controlled with 2 or more Oral Antihyperglycemic Me... | 2014-05-28 | due-trials |
| Reported results | 2012-004229-25 | A Randomized, Double-Blind Trial Comparing the Effect of Dulaglutide 1.5 mg with Placebo on Glycemic Control in Patients with Type 2 Diabetes on Basal Insulin Glargine (AWARD-9: Assessment of Weekly... | 2015-10-15 | due-trials |
| Exempt, with results | 2012-004496-40 | Study of the Safety and Efficacy of LY3016859 after Multiple Intravenous Dosing in Diabetic Nephropathy Patients | 2015-08-15 | not-yet-due |
| Reported results | 2012-004866-16 | A Randomized, Double-Blind, Placebo-Controlled Parallel Study with an Open-Label Extension to Assess the Impact of Testosterone Solution on Total Testosterone, Sex Drive and Energy in Hypogonadal Men. | 2015-06-30 | due-trials |
| Reported results | 2012-005174-56 | A Comparison of Pharmacodynamics When Receiving a Double Dose of Insulin Peglispro or Insulin Glargine in Patients with Type 2 Diabetes Mellitus: A Double-Blind, Crossover Design Study: The IMAGINE 8... | 2015-07-10 | due-trials |
| Ongoing | 2012-005476-33 | A Randomized, Controlled Phase 2 Study Evaluating LY2875358 plus Erlotinib versus Erlotinib as First-Line Treatment in Metastatic Non?Small Cell Lung Cancer Patients with Activating EGFR Mutations Who... | not-yet-due | |
| Reported results | 2012-005477-31 | A Randomized, Open-Label Phase 2 Study Evaluating LY2875358 Plus Erlotinib and LY2875358 Monotherapy in MET Diagnostic Positive NSCLC Patients with Acquired Resistance to Erlotinib | 2016-05-31 | due-trials |
| Reported results | 2013-000622-55 | A Phase 2 Efficacy and Safety Dose-Ranging Study of LY3015014 in Patients with Primary Hypercholesterolemia | 2014-06-06 | due-trials |
| Reported results | 2013-001119-54 | Effect of Passive Immunization on the Progression of Mild Alzheimer?s Disease: Solanezumab (LY2062430) versus Placebo Efecto de la inmunización pasiva en la progresión de la enfermedad de Alzheime... | 2017-02-17 | due-trials |
| Reported results | 2013-001194-25 | A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Trial of Tadalafil for Duchenne Muscular Dystrophy | 2016-03-31 | due-trials |
| Reported results Terminated | 2013-001473-24 | An Individualized treatMent aPproach for oldER patIents: A randomized, controlled stUdy in type 2 diabetes Mellitus | 2015-10-14 | due-trials |
| Reported results | 2013-003235-30 | Phase 2/3 Study of Monotherapy LY2157299 Monohydrate in Very Low-, Low-, and Intermediate-Risk Patients with Myelodysplastic Syndromes | 2017-09-24 | due-trials |
| Reported results | 2013-003552-21 | Comparison of the Oxyntomodulin Analog, LY2944876, to Once-Weekly Exenatide and to Placebo in Patients with Type 2 Diabetes. | 2015-10-23 | due-trials |
| Reported results | 2013-003834-33 | Protocol I1R-MC-GLDI The Effect of LY2409021 on Blood Pressure and Pulse Rate, as Assessed by Ambulatory Blood Pressure Monitoring, in Subjects with Type 2 Diabetes Mellitus | 2015-01-20 | due-trials |
| Reported results Terminated | 2013-004275-12 | A Phase 2, Double-Blind, Placebo-Controlled Trial to Evaluate the Safety and Efficacy of LY2409021 Compared to Sitagliptin in Subjects with Type 2 Diabetes Mellitus | 2015-09-28 | due-trials |
| Ongoing | 2013-004662-33 | A Randomized Phase 3 Study of LY2835219 plus Best Supportive Care versus Erlotinib plus Best Supportive Care in Patients with Stage IV NSCLC with a Detectable KRAS Mutation Who Have Progressed After P... | not-yet-due | |
| Ongoing | 2013-004728-13 | A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study of Fulvestrant with or without Abemaciclib, a CDK4/6 Inhibitor, for Women with Hormone Receptor Positive, HER2 Negative Locally Advanced o... | not-yet-due | |
| Reported results | 2013-005548-27 | A Phase 2 Study of LY2835219 for Patients with Previously Treated Hormone Receptor Positive, HER2 Negative Metastatic Breast Cancer | 2018-10-22 | due-trials |
| Ongoing | 2014-001502-18 | A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study of Nonsteroidal Aromatase Inhibitors (Anastrozole or Letrozole) Plus LY2835219, a CDK4/6 Inhibitor, or Placebo in Postmenopausal Women Wit... | not-yet-due | |
| Reported results | 2014-002240-40 | A Randomized, Double-Blind, Placebo-Controlled Phase 3 Study of Capecitabine and Cisplatin With or Without Ramucirumab as First-line Therapy in Patients With Metastatic Gastric or Gastroesophageal Jun... | 2020-08-14 | due-trials |
| Reported results | 2014-002601-38 | A 24-Month, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group, Efficacy, Safety, Tolerability, Biomarker and Pharmacokinetics Study of AZD3293 in Early Alzheimer's Disease (The... | 2018-10-04 | due-trials |
| Listed as ongoing, but also has a completion date and reported results | 2014-003655-66 | A Phase 3, Randomized, Double-Bind, Placebo-Controlled Study of Ramucirumab plus Docetaxel versus Placebo plus Docetaxel in Patients with Locally Advanced or Unresectable or Metastatic Urothelial Carc... | 2022-07-26 | bad-data |
| Reported results | 2014-003791-23 | Protocol I4T-MC-JVDB Randomized Phase 2 Trial Evaluating Pharmacokinetics and Safety of Four Ramucirumab Dosing Regimens in Second Line Gastric or Gastroesophageal Junction Adenocarcinoma | 2020-06-05 | due-trials |
| Reported results | 2014-004010-28 | A Phase 2 Study of Abemaciclib in Patients with Brain Metastases Secondary to Hormone Receptor Positive Breast Cancer | 2019-11-27 | due-trials |
| Ongoing, reported early | 2014-004824-22 | A Multicenter, Randomized, Double-Blind Study of Erlotinib in Combination with Ramucirumab or Placebo in Previously Untreated Patients with EGFR Mutation-Positive Metastatic Non-Small Cell Lung Cancer | not-yet-due | |
| Reported results | 2014-004832-20 | A Randomized Phase 2 Study of Abemaciclib (LY2835219) versus Docetaxel in Patients with Stage IV Squamous Non-Small Cell Lung Cancer Previously Treated with Platinum-based Chemotherapy | 2020-07-29 | due-trials |
| Exempt, with results | 2014-005024-10 | A Phase 1b/Randomized Phase 2 Study to Evaluate LY3039478 in Combination with Dexamethasone in T-ALL/T-LBL Patients | 2018-01-15 | not-yet-due |
| Exempt, with results | 2014-005042-21 | A Single-Arm, Multicenter, Phase 1b Study with an Expansion Cohort to Evaluate Safety and Efficacy of Necitumumab in Combination with Abemaciclib in Treatment of Patients with Stage IV Non-Small Cell ... | 2019-05-28 | not-yet-due |
| Reported results | 2014-005067-32 | Protocol I4T-MC-JVCZ Randomized Phase 2 Trial Evaluating Alternative Ramucirumab Doses in Combination with Paclitaxel in Second-Line Metastatic or Locally Advanced, Unresectable Gastric or Gastroesoph... | 2018-12-28 | due-trials |
| Reported results | 2014-005068-13 | Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study of Ramucirumab and Best Supportive Care (BSC) Versus Placebo and BSC as Second-Line Treatment in Patients With Hepatocellular Carcinoma and ... | 2021-11-19 | due-trials |
| Reported results | 2014-005429-11 | A Phase 3 Randomized, Double-Blind, Placebo-Controlled Study of LY2951742 with a Long-Term Open-Label Extension in Patients with Chronic Cluster Headache | 2019-08-14 | due-trials |
| Reported results | 2014-005486-75 | neoMONARCH: A Phase 2 Neoadjuvant Trial Comparing the Biological Effects of 2 Weeks of Abemaciclib (LY2835219) in Combination with Anastrozole to those of Abemaciclib Monotherapy and Anastrozole Monot... | 2018-02-12 | due-trials |
| Listed as ongoing, but also has a completion date | 2015-000134-30 | A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Trial of Doxorubicin plus Olaratumab versus Doxorubicin plus Placebo in Patients with Advanced or Metastatic Soft Tissue Sarcoma | 2024-06-27 | bad-data |
| Reported results | 2015-000149-22 | A Phase 3 Randomized, Double-Blind, Placebo-Controlled Study of LY2951742 in Patients with Episodic Cluster Headache | 2018-06-04 | due-trials |
| Reported results | 2015-000190-12 | A Multicenter, Randomized, Double-Blind Study Comparing the Efficacy and Safety of Ixekizumab Dosing Regimens in Patients with Moderate-to-Severe Plaque Psoriasis | 2017-08-03 | due-trials |
| Reported results | 2015-000892-28 | A 52-Week Multicenter, Randomized, Blinded, Parallel Group Study Comparing the Efficacy and Safety of Ixekizumab to Ustekinumab in Patients with Moderate to Severe Plaque Psoriasis Studio di 52sett... | 2017-10-05 | due-trials |
| Listed as ongoing, but also has a completion date and reported results | 2015-001316-34 | A Phase 1b (Open-Label) / Phase 2 (Randomized, Double-Blinded) Study Evaluating Gemcitabine and Docetaxel With or Without Olaratumab in the Treatment of Advanced Soft Tissue Sarcoma | 2021-04-27 | bad-data |
| Reported results | 2015-001882-17 | A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of LY2951742 in Patients with Episodic Migraine - the EVOLVE-2 Study | 2018-10-05 | due-trials |
| Listed as ongoing, but also has a completion date and reported results | 2015-001883-21 | A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of LY2951742 in Patients with Chronic Migraine - the REGAIN Study | 2021-07-14 | bad-data |
| Reported results | 2015-001884-38 | A Phase 3, Long-Term, Open-Label Safety Study of LY2951742 in Patients with Migraine. | 2018-08-14 | due-trials |
| Reported results | 2015-002052-27 | A PHASE 3, RANDOMIZED, DOUBLE-BLIND, VEHICLE-CONTROLLED EFFICACY AND SAFETY STUDY OF DRM04 IN SUBJECTS WITH AXILLARY HYPERHIDROSIS | 2016-03-24 | due-trials |
| Reported results | 2015-002093-20 | A Phase 1b/2 Dose Escalation and Cohort Expansion Study of the Safety, Tolerability and Efficacy of a Novel Transforming Growth Factor-beta Receptor I Kinase Inhibitor (Galunisertib) Administered in C... | 2020-07-08 | due-trials |
| Reported results | 2015-002095-24 | Protocol H9X-MC-GBGE(a) A Randomized, Parallel-Arm, Double-Blind Study of Efficacy and Safety of Dulaglutide When Added to SGLT2 Inhibitors in Patients with Type 2 Diabetes Mellitus (AWARD-10: Assess... | 2017-02-03 | due-trials |
| Reported results | 2015-002163-42 | AN OPEN-LABEL STUDY ASSESSING LONG-TERM SAFETY OF DRM04 IN SUBJECTS WITH PRIMARY AXILLARY HYPERHIDROSIS | 2016-12-08 | due-trials |
| Reported results | 2015-002433-22 | A Phase 3, Multicenter Study with a 36-Week Open-Label Period Followed by a Randomized Double-Blind Withdrawal Period from Week 36 to Week 104 to Evaluate the Long Term Efficacy and Safety of Ixekizum... | 2018-10-30 | due-trials |
| Reported results | 2015-002628-14 | A Multicenter, Randomized, Double-Blind Study Comparing the Efficacy and Safety of Ixekizumab Versus Placebo in Patients with Moderate-to-Severe Genital Psoriasis | 2018-02-21 | due-trials |
| Reported results | 2015-002649-69 | A 24-Week Multicenter, Randomized, Open-Label, Parallel Group Study Comparing the Efficacy and Safety of Ixekizumab to Fumaric Acid Esters and Methotrexate in Patients with Moderate-to-Severe Plaque P... | 2017-11-14 | due-trials |
| Reported results | 2015-003123-57 | A Phase 2, Multicenter, Randomized, Double-Blind, Parallel, Placebo-Controlled Study of LY3074828 in Subjects with Moderate to Severe Ulcerative Colitis | 2019-05-07 | due-trials |
| Reported results | 2015-003289-97 | A Randomized, Double-Blind, Placebo-Controlled, 2-Part Phase 2 Study to Evaluate the Safety and Efficacy of LY3337641 in Adult Subjects with Rheumatoid Arthritis: The RAjuvenate Study | 2018-08-20 | due-trials |
| Listed as ongoing, but also has a completion date and reported results | 2015-003400-24 | monarcHER: A Phase 2, Randomized, Multicenter, 3-Arm, Open-Label Study to Compare the Efficacy of Abemaciclib plus Trastuzumab with or without Fulvestrant to Standard-of-Care Chemotherapy of Physician... | 2023-11-09 | bad-data |
| No trial status on register | 2015-003424-31 | Treatment of Conditions Expected to Benefit from JAK 1/2 Inhibition: CANDLE, CANDLE-Related Conditions, SAVI, and Severe Juvenile Dermatomyositis | bad-data | |
| Ongoing | 2015-003582-28 | A Phase 2 Basket Study of the Oral TRK Inhibitor Larotrectinib in Subjects with NTRK Fusion-Positive Tumors P/0401/2019 Eine Phase-II-Basket-Studie des oralen TRK-Inhibitors Larotrectinib bei Prob... | not-yet-due | |
| Reported results | 2015-003932-11 | A Multicenter, Randomized, Double-Blind, Active and Placebo-Controlled 16 Week Study Followed by Long Term Evaluation of Efficacy and Safety of Ixekizumab (LY2439821) in bDMARD-Naive Patients with Rad... | 2018-10-17 | due-trials |
| Reported results | 2015-003937-84 | A Multicenter, Randomized, Double-Blind, Placebo-Controlled 16 Week Study Followed by Long Term Evaluation of Efficacy and Safety of Ixekizumab (LY2439821) in TNFi-Experienced Patients with Radiograph... | 2019-05-03 | due-trials |
| Reported results | 2015-003938-27 | A 52 Week Multicenter, Randomized, Double-Blind, Placebo Controlled Study to Evaluate the Efficacy and Safety of Ixekizumab (LY2439821) in bDMARD Naive Patients with Nonradiographic Axial Spondyloarth... | 2019-05-07 | due-trials |
| Reported results | 2015-004404-35 | A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Phase 2 Study of Baricitinib in Patients with Systemic Lupus Erythematosus (SLE) | 2017-11-09 | due-trials |
| Ongoing | 2015-004699-31 | Randomized, Double-Blind, Phase 2 Study of Ramucirumab or Merestinib or Placebo plus Cisplatin and Gemcitabine as First-Line Treatment in Patients with Advanced or Metastatic Biliary Tract Cancer | not-yet-due | |
| Reported results | 2015-005069-21 | A Phase 2 Study of LY2606368 in Patients with Extensive Stage Disease Small Cell Lung Cancer | 2019-02-20 | due-trials |
| Ongoing | 2015-005156-94 | Protocol I3Y-MC-JPCE A Phase 1b Study of Abemaciclib in Combination with Pembrolizumab for Patients with Stage IV Non-Small Cell Lung Cancer or Hormone Receptor Positive, HER2 Negative Breast Cancer | not-yet-due | |
| Reported results | 2015-005234-21 | A Phase 3b Multicenter, Single-Arm, Open-Label Safety Study of LY2951742 (galcanezumab) in Patients with Episodic or Chronic Cluster Headache | 2021-01-21 | due-trials |
| Reported results | 2015-005356-99 | A Prospective, Randomized, Double-Blind Comparison of LY900014 to Insulin Lispro with an Open-Label Postprandial LY900014 Treatment Group, in Combination with Insulin Glargine or Insulin Degludec, in ... | 2019-08-22 | due-trials |
| Reported results | 2015-005357-12 | Protocol I8B-MC-ITRN A Prospective, Randomized, Double-Blind Comparison of LY900014 to Insulin Lispro, Both in Combination with Insulin Glargine or Insulin Degludec in Adults with Type 2 Diabetes | 2019-03-13 | due-trials |
| Reported results | 2015-005358-36 | A Prospective, Randomized, Double Blind Comparison of LY900014 to Humalog in Adults with Type 1 Diabetes Using Continuous Subcutaneous Insulin Infusion Studio prospettico, randomizzato, in doppio c... | 2020-01-06 | due-trials |
| Reported results | 2015-005625-39 | A Randomized, Double-Blind, Placebo-Controlled and Delayed-Start Study of LY3314814 in Mild Alzheimer's Disease Dementia (The DAYBREAK Study) Studio randomizzato, in doppio cieco, controllato con p... | 2018-12-31 | due-trials |
| Reported results | 2015-005674-37 | An Open-label, LonG-term, Safety Study of LAsmiDItan (100 mg and 200 mg) in the Acute Treatment Of MigRaine (GLADIATOR) | 2019-08-20 | due-trials |
| Trial is outside EEC, and reported results | 2015-005721-39 | A Phase 1, Open-Label, Dose-Escalation Study of Olaratumab as a Single Agent and in Combination with Doxorubicin, Vincristine/Irinotecan, or High-dose Ifosfamide in Pediatric Patients with Relapsed or... | bad-data | |
| Reported results Terminated | 2016-000108-27 | A 24-Month, Phase 3, Multicenter, Placebo-Controlled Study of Efficacy and Safety of Solanezumab versus Placebo in Prodromal Alzheimer’s Disease | 2017-05-08 | due-trials |
| Completed, but no date, and reported results | 2016-000288-18 | A Randomized, Open-Label, Phase 2 Study of Abemaciclib plus Tamoxifen or Abemaciclib Alone, in Women with Previously Treated Hormone Receptor-Positive, HER2-Negative, Metastatic Breast Cancer | bad-data | |
| Listed as ongoing, but also has a completion date and reported results | 2016-000361-22 | A Randomized, Double-Blind Study with an Open-Label Extension Comparing the Effect of Once-Weekly Dulaglutide with Placebo in Pediatric Patients with Type 2 Diabetes Mellitus | 2022-01-12 | bad-data |
| Reported results | 2016-001098-34 | Protocol I6T-MC-AMAF A Phase 2, Multicenter, Randomized, Parallel-arm, Placebo-Controlled Study of LY3074828 in Subjects with Moderate to Severe Plaque Psoriasis | 2019-05-08 | due-trials |
| Completed, but no date, and reported results | 2016-001099-31 | A Phase 1b (Open-Label) / Phase 2 (Randomized, Double-Blinded) Study Evaluating Nab-Paclitaxel and Gemcitabine With or Without Olaratumab in the Treatment of First-Line Metastatic Pancreatic Cancer | bad-data | |
| Ongoing | 2016-001317-25 | A Single-Arm, Phase 2 Study of Ramucirumab in Combination with Weekly Docetaxel in Patients with Stage IV Non-Small Cell Lung Cancer Following Disease Progression after Prior Platinum-based Chemothera... | not-yet-due | |
| Trial is outside EEC, and reported results | 2016-001502-42 | Effect of Early Growth Hormone Treatment on Long-term Growth and Skeletal Maturation in Girls With Turner Syndrome | bad-data | |
| Listed as ongoing, but also has a completion date | 2016-002041-31 | A Single-Arm, Multicenter, Phase 2 Study of Gemcitabine-Carboplatin Chemotherapy Plus Necitumumab in the First-Line Treatment of Patients with Locally Advanced or Metastatic Squamous Non-Small Cell Lu... | 2016-11-11 | bad-data |
| Reported results | 2016-002071-96 | A Single-Arm, Multicenter, Open-Label, Phase 2 Study of nab®-Paclitaxel (Abraxane®) and Carboplatin Chemotherapy plus Necitumumab (LY3012211) in the First-Line Treatment of Patients with Stage IV Squa... | 2019-11-06 | due-trials |
| Listed as ongoing, but also has a completion date and reported results | 2016-002204-84 | A Phase 2, Multicenter, Randomized, Parallel-Arm, Placebo- Controlled Study of LY3074828 in Subjects with Active Crohn’s Disease (SERENITY) | 2021-02-05 | bad-data |
| Reported results | 2016-002218-36 | An Adaptive, Open-Label, Randomized Phase 2 Study of Abemaciclib as a Monotherapy and in Combination with Other Agents Versus Choice of Standard of Care (Gemcitabine or Capecitabine) in Patients with ... | 2018-11-09 | due-trials |
| Reported results | 2016-002494-34 | A Phase 2, Double-Blind, Placebo-Controlled, 18-Week Trial of Investigational Dulaglutide Doses versus Placebo in Patients with Type 2 Diabetes on Metformin Monotherapy | 2017-08-14 | due-trials |
| Reported results | 2016-002634-69 | Protocol I1F-MC-RHBY A Multicenter, Long-Term Extension Study of 104 Weeks, Including a Double-Blind, Placebo-Controlled 40-Week Randomized Withdrawal-Retreatment Period, to Evaluate the Maintenance o... | 2021-05-27 | due-trials |
| Reported results | 2016-003331-38 | Multicenter, Double-Blind, Randomized, Active- and Placebo Controlled Study to Evaluate Safety, Tolerability, and Efficacy of Ixekizumab in Patients from 6 to Less than 18 Years of Age with Moderate-t... | 2021-03-23 | due-trials |
| Reported results | 2016-003440-36 | A Randomized, Double-Blind, Delayed-Start Study of LY3314814 (AZD3293) in Early Alzheimer’s Disease Dementia (Extension of Study AZES, The AMARANTH Study) | 2018-10-04 | due-trials |
| Ongoing | 2016-003498-16 | A Phase 1/2 Study of the Oral TRK Inhibitor LOXO-101 in Pediatric Patients with Advanced Solid or Primary Central Nervous System Tumors | not-yet-due | |
| Reported results | 2016-003858-33 | A Randomized Phase 3 Study of AM0010 in Combination with FOLFOX Compared with FOLFOX Alone as Second-line Therapy in Patients with Metastatic Pancreatic Cancer that has Progressed During or Following ... | 2020-03-05 | due-trials |
| Reported results | 2016-004179-33 | A Phase 2 Study of Once-Weekly LY3298176 Compared with Placebo and Dulaglutide in Patients with Type 2 Diabetes Mellitus | 2019-03-19 | due-trials |
| Ongoing | 2016-004276-21 | A Phase 2, Randomized, Double-blind, Placebo-Controlled Study of Abiraterone Acetate Plus Prednisone with or without Abemaciclib in Patients with Metastatic Castration-Resistant Prostate Cancer | not-yet-due | |
| Other | 2016-004362-26 | A Randomized, Open-Label, Phase 3 Study of Abemaciclib Combined with Standard Adjuvant Endocrine Therapy versus Standard Adjuvant Endocrine Therapy Alone in Patients with High Risk, Node Positive, Ear... | not-yet-due | |
| Reported results | 2016-004585-25 | A 52-Week Multicenter, Randomized, Open-Label, Parallel-Group Study Evaluating the Efficacy and Safety of Ixekizumab versus Adalimumab in Patients with Psoriatic Arthritis Who Are Biologic Disease-Mod... | 2019-09-04 | due-trials |
| Listed as ongoing, but also has a completion date | 2016-004675-52 | A Multicenter, Randomized, Double-Blind, Placebo-Controlled, 24 Week Study Followed by Long-Term Treatment for Evaluation of Efficacy and Safety of Baricitinib in Patients with Active Psoriatic Arthri... | 2019-05-08 | bad-data |
| Trial is outside EEC, and reported results | 2017-000095-28 | A Phase II Study of Pemetrexed in Children with Recurrent Malignancies | bad-data | |
| Trial is outside EEC, and reported results | 2017-000211-16 | F1J-MC-HMFN (a) An Open-Label Study of Tolerability, Safety, and Pharmacokinetics of Duloxetine in the Treatment of Children and Adolescents With Major Depressive Disorder | bad-data | |
| Trial is outside EEC, and reported results | 2017-000685-29 | A Phase 3b, Randomized, Open-Label Assessment of Response to Various Doses of Atomoxetine Hydrochloride in Korean Pediatric Outpatients With Attention-Deficit/Hyperactivity Disorder | bad-data | |
| Trial is outside EEC, and reported results | 2017-000686-68 | Long-Term Extension, Open-Label Study of Atomoxetine Hydrochloride in Child Outpatients With Attention-Deficit/Hyperactivity Disorder | bad-data | |
| Trial is outside EEC, and reported results | 2017-000739-15 | A Double-Blind Placebo Controlled Study of Atomoxetine Hydrochloride for the Treatment of ADHD in Children and Adolescents With ADHD and Comorbid Dyslexia | bad-data | |
| Trial is outside EEC, and reported results | 2017-000740-18 | Evaluation of Academic Performance in Asian Children Aged 8 to 11 Years With Attention-Deficit/Hyperactivity Disorder Treated With Atomoxetine Hydrochloride | bad-data | |
| Exempt | 2017-000800-59 | A Phase 1 /2 Study of Oral Selpercatinib (LOXO-292) in Patients with Advanced Solid Tumors, Including RET Fusion-Positive Solid Tumors, Medullary Thyroid Cancer, and Other Tumors with RET Activation (... | 2018-06-12 | not-yet-due |
| Reported results | 2017-000870-12 | A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study to Evaluate the Efficacy and Safety of Baricitinib in Adult Patients with Moderate to Severe Atopic Dermatitis | 2019-01-04 | due-trials |
| Reported results | 2017-000871-10 | A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study to Evaluate the Efficacy and Safety of Baricitinib in Patients with Moderate to Severe Atopic Dermatitis | 2018-12-12 | due-trials |
| Listed as ongoing, but also has a completion date and reported results | 2017-000873-35 | Protocol I4V-MC-JAHN: A Phase 3 Multicenter, Double-Blind Study to Evaluate the Long-Term Safety and Efficacy of Baricitinib in Adult Patients with Atopic Dermatitis | 2023-09-04 | bad-data |
| Trial is outside EEC, and reported results | 2017-001162-21 | An Open-Label, Randomized, Crossover Trial of CSII Reservoir In-use Comparing Insulin Lispro Formulation to Insulin Aspart in Patients with Type 1 Diabetes Mellitus | bad-data | |
| Trial is outside EEC, and reported results | 2017-001243-12 | An Open-Label, Dose-Ranging Study of Prasugrel in Pediatric Patients With Sickle Cell Disease | bad-data | |
| Trial is outside EEC, and reported results | 2017-001598-18 | A Double-Blind, Efficacy and Safety Study of Duloxetine Versus Placebo in the Treatment of Children and Adolescents With Major Depressive Disorder | bad-data | |
| Trial is outside EEC, and reported results | 2017-001599-46 | A Double-Blind, Efficacy and Safety Study of Duloxetine Versus Placebo in the Treatment of Children and Adolescents With Generalized Anxiety Disorder | bad-data | |
| Reported results | 2017-002374-39 | Protocol I8B-MC-ITSI A Prospective, Randomized, Double-Blind, Crossover Comparison Evaluating Compatibility and Safety of LY900014 and Insulin Lispro with an External Continuous Subcutaneous Insulin I... | 2018-09-04 | due-trials |
| Exempt, with results | 2017-003220-78 | A Study to Evaluate the Pharmacokinetics and Glucodynamics of LY900014 Compared to Humalog in Children, Adolescents, and Adults with Type 1 Diabetes Mellitus | 2019-11-14 | not-yet-due |
| Listed as ongoing, but also has a completion date and reported results | 2017-003229-14 | A Phase 3, Multicenter, Randomized, Double-Blind, Parallel, Placebo-Controlled Induction Study of Mirikizumab in Conventional-Failed and Biologic-Failed Patients with Moderately to Severely Active Ulc... | 2022-04-01 | bad-data |
| Listed as ongoing, but also has a completion date and reported results | 2017-003238-96 | A PHASE 3, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PARALLEL-ARM, PLACEBO-CONTROLLED MAINTENANCE STUDY OF MIRIKIZUMAB IN PATIENTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS (LUCENT 2) | 2022-02-04 | bad-data |
| Reported results | 2017-003286-10 | A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study Comparing the Efficacy and Safety of Mirikizumab to Secukinumab and Placebo in Patients with Moderate-to-Severe Plaque Psoriasis | 2020-06-03 | due-trials |
| Reported results | 2017-003298-32 | A Multicenter Study with a Randomized, Double-Blind, Placebo-Controlled Induction Dosing Period Followed by a Randomized Withdrawal Maintenance Dosing Period to Evaluate the Efficacy and Safety of Mir... | 2020-01-16 | due-trials |
| Listed as ongoing, but also has a completion date and reported results | 2017-003299-30 | A Multicenter, Long-Term Extension to Evaluate the Long Term Safety and Maintenance of Treatment Effect of Mirikizumab in Patients with Moderate to Severe Plaque Psoriasis | 2022-02-21 | bad-data |
| Listed as ongoing, but also has a completion date | 2017-003399-30 | A Prospective, Randomized, Double-Blind Comparison of LY900014 and Fiasp®, Both in Combination with Basal Insulin in Adults with Type 1 Diabetes, PRONTO-Compare | 2018-10-30 | bad-data |
| Reported results | 2017-003490-33 | A Randomized, Double-Blind, Parallel Arm Study of the Efficacy and Safety of Investigational Dulaglutide Doses When Added to Metformin in Patients with Type 2 Diabetes Mellitus | 2019-10-10 | due-trials |
| Listed as ongoing, but also has a completion date and reported results | 2017-004009-42 | A Phase 2 Study of Prexasertib in Platinum-Resistant or Refractory Recurrent Ovarian Cancer | 2020-10-03 | bad-data |
| Ongoing | 2017-004092-31 | A Phase 3, Multicenter, Open-Label Extension Study to Evaluate the Long-Term Efficacy and Safety of Mirikizumab in Patients with Moderately to Severely Active Ulcerative Colitis (LUCENT 3) Studio d... | not-yet-due | |
| Exempt, with results | 2017-004246-20 | A Phase 1 Study of the TRK Inhibitor Selitrectinib (BAY 2731954) in Adult and Pediatric Subjects with Previously Treated NTRK Fusion Cancers Formerly: A Phase 1/2 Study of the TRK Inhibitor LOXO-195 ... | 2023-01-30 | not-yet-due |
| Ongoing | 2017-004351-23 | A Randomized, Double-Blind, Placebo-Controlled Study of Galcanezumab in Patients 6 to 17 Years of Age with Episodic Migraine – the REBUILD-1 Study | not-yet-due | |
| Other | 2017-004471-31 | A Phase 3 Multicenter Study to Evaluate the Long-Term Safety and Efficacy of Baricitinib in Patients from 1 Year to <18 Years of Age with Juvenile Idiopathic Arthritis (JIA) | not-yet-due | |
| Ongoing | 2017-004495-60 | A Randomized, Double-Blind, Placebo-Controlled, Withdrawal, Safety and Efficacy Study of Oral Baricitinib in Patients from 1 Year to Less Than 18 Years Old with Systemic Juvenile Idiopathic Arthritis ... | not-yet-due | |
| Listed as ongoing, but also has a completion date and reported results | 2017-004518-24 | A Randomized, Double-Blind, Placebo-Controlled, Withdrawal, Safety and Efficacy Study of Oral Baricitinib in Patients from 2 Years to Less Than 18 Years Old with Juvenile Idiopathic Arthritis (JIA) | 2022-01-26 | bad-data |
| Listed as ongoing, but also has a completion date and reported results | 2017-004574-34 | A Phase 3, Multicenter, Double-Blind, Randomized, Placebo-Controlled Study Evaluating the Safety and Efficacy of Baricitinib in Combination with Topical Corticosteroids in Adult Patients with Moderate... | 2023-04-20 | bad-data |
| Listed as ongoing, but also has a completion date and reported results | 2017-005026-37 | A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Phase 3 Study of Baricitinib in Patients with Systemic Lupus Erythematosus | 2021-11-01 | bad-data |
| Listed as ongoing, but also has a completion date and reported results | 2017-005027-25 | A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Phase 3 Study of Baricitinib in Patients with Systemic Lupus Erythematosus | 2021-10-20 | bad-data |
| Listed as ongoing, but also has a completion date and reported results | 2017-005028-11 | A Phase 3, Double-Blind, Multicenter Study to Evaluate the Long-Term Safety and Efficacy of Baricitinib in Patients with Systemic Lupus Erythematosus (SLE) | 2022-04-01 | bad-data |
| Other | 2018-000349-38 | I4V-MC-JAIP A Phase 3, Multicenter, Randomized, Double blind, Placebo controlled, Parallel group, Outpatient Study Evaluating the Pharmacokinetics, Efficacy, and Safety of Baricitinib in Pediatric Pat... | not-yet-due | |
| Reported results | 2018-000600-42 | A Randomized, Double-Blind, Placebo-Controlled Study of Galcanezumab in Adults with Treatment-Resistant Migraine - The CONQUER Study | 2019-09-19 | due-trials |
| Ongoing | 2018-000681-10 | Multicenter, Open-label, Efficacy, Safety, Tolerability, and Pharmacokinetic Study of Subcutaneous Ixekizumab with Adalimumab Reference Arm, in Children with Juvenile Idiopathic Arthritis Subtypes of ... | not-yet-due | |
| Listed as ongoing, but also has a completion date and reported results | 2018-001661-17 | Randomized Controlled Trial of Lasmiditan Over Four Migraine Attacks | 2021-07-08 | bad-data |
| Reported results | 2018-001726-26 | A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study to Evaluate the Efficacy and Safety of Baricitinib in Combination with Topical Corticosteroids in Adult Patients with Moderat... | 2019-08-22 | due-trials |
| Reported results | 2018-001853-28 | An Open-Label, Randomized Phase 2 Study of the Impact of Food on Tolerability when Receiving Abemaciclib for Patients with Previously Treated Hormone Receptor-Positive, HER2-Negative, Metastatic Breas... | 2023-03-09 | due-trials |
| Listed as ongoing, but also has a completion date and reported results | 2018-002371-18 | A Prospective, Randomized, Double-Blind Comparison of LY900014 to Humalog with an Open-Label Postprandial LY900014 Treatment Group in Children and Adolescents with Type 1 Diabetes PRONTO-PEDS | 2021-07-02 | bad-data |
| Reported results Terminated | 2018-002401-56 | A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Phase 2 Study to Evaluate the Efficacy and Safety of LY3375880 in Adult Subjects with Moderate-to-Severe Atopic Dermatitis | 2020-02-27 | due-trials |
| Reported results | 2018-002618-11 | Efficacy and Safety of LY3298176 Once Weekly versus Insulin Glargine in Patients with Type 2 Diabetes and Increased Cardiovascular Risk | 2021-04-22 | due-trials |
| Exempt | 2018-003340-24 | A Phase 1/2 Study of Oral LOXO-305 in Patients with Previously Treated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL) or Non-Hodgkin Lymphoma (NHL) | not-yet-due | |
| Ongoing | 2018-003351-37 | A Randomized, Active Controlled, Parallel Group, Phase 3b/4 Study of Baricitinib in Patients with Rheumatoid Arthritis Μια ανοικτή, τυχαιοποιημένη, ελεγχόμενη δοκιμή με δραστικό παράγοντα σύγκριση... | not-yet-due | |
| Reported results | 2018-003365-34 | A Randomized, Double-Blind, Placebo-Controlled, Proof-of-Concept Study Evaluating the Efficacy and Safety of Baricitinib (LY3009104) in Patients with Primary Biliary Cholangitis Who Have an Inadequat... | 2019-09-26 | due-trials |
| Reported results | 2018-003422-84 | A Randomized, Phase 3, Open-Label Trial Comparing the Effect of LY3298176 versus Titrated Insulin Degludec on Glycemic Control in Patients with Type 2 Diabetes | 2021-04-01 | due-trials |
| Listed as ongoing, but also has a completion date | 2018-004242-42 | A Randomized, Open-Label Phase 1/2 Study Evaluating Ramucirumab in Pediatric Patients and Young Adults with Relapsed, Recurrent, or Refractory Desmoplastic Small Round Cell Tumor. | 2024-05-20 | bad-data |
| Listed as ongoing, but also has a completion date and reported results | 2018-004243-23 | A Randomized, Open-Label Phase 1/2 Study Evaluating Ramucirumab in Pediatric Patients and Young Adults with relapsed, Recurrent, or Refractory Synovial Sarcoma. Studio di Fase 1/2, Randomizzato, in... | 2023-03-15 | bad-data |
| Other | 2018-004422-29 | A Phase 3, Randomized, Open-Label Trial Comparing Efficacy and Safety of Tirzepatide versus Semaglutide Once Weekly as Add-on Therapy to Metformin in Patients with Type 2 Diabetes (SURPASS-2) | not-yet-due | |
| Listed as ongoing, but also has a completion date and reported results | 2018-004614-18 | A Phase 3, Multicenter, Randomized, Double-Blind, Placebo- and Active-Controlled, Treat-Through Study to Evaluate the Efficacy and Safety of Mirikizumab in Patients with Moderately to Severely Active ... | 2023-10-02 | bad-data |
| Other | 2018-004622-28 | A Randomized, Double-Blind, Placebo-Controlled Study of Galcanezumab in Adolescent Patients 12 to 17 Years of Age with Chronic Migraine – the REBUILD-2 Study | not-yet-due | |
| Other | 2019-000119-10 | An Open-label, Active-Controlled, Safety and Efficacy Study of Oral Baricitinib in Patients from 2 Years to Less Than 18 Years Old with Active Juvenile Idiopathic Arthritis-Associated Uveitis or Chron... | not-yet-due | |
| Other | 2019-000212-28 | A Phase 1/2 Study of the Oral RET Inhibitor LOXO-292 in Pediatric Patients with Advanced RET-Altered Solid or Primary Central Nervous System Tumors | not-yet-due | |
| Trial is outside EEC, and reported results | 2019-000419-98 | Neurophysiology of Attention-Deficit/Hyperactivity Disorder (ADHD) and Comorbid Dyslexia: Functional Magnetic Resonance Imaging (fMRI) Measures of Brain Activation During Attention and Reading Tasks P... | bad-data | |
| Reported results | 2019-000860-99 | A Randomized, Phase 3, Double-blind Trial Comparing the Effect of the Addition of Tirzepatide versus Placebo in Patients with Type 2 Diabetes Inadequately Controlled on Insulin Glargine with or withou... | 2021-01-13 | due-trials |
| Exempt | 2019-001042-18 | A Phase 1 Study of Aurora Kinase A Inhibitor LY3295668 erbumine as a Single Agent and in Combination in Patients with Relapsed/Refractory Neuroblastoma | not-yet-due | |
| Trial is outside EEC, and reported results | 2019-001298-96 | Protocol I6T-MC-AMBU A Mulitcenter, Open-Label PK Study of Mirikizumab in Pediatric Patients with Moderately to Severely Active Ulcerative Colitis | bad-data | |
| Listed as ongoing, but also has a completion date | 2019-001550-26 | A Randomized, Double-Blind, Placebo-Controlled Phase 2 Study Comparing the Efficacy and Safety of Tirzepatide versus Placebo in Patients with Nonalcoholic Steatohepatitis (NASH) | 2024-01-10 | bad-data |
| Reported results | 2019-001653-99 | A Phase 3b, Randomized, Double-Blind, Parallel-Arm, Placebo- and Active- Controlled Treat-Through Study of Mirikizumab and Vedolizumab in Participants with Moderately to Severely Active Ulcerative Col... | 2021-04-16 | due-trials |
| Other | 2019-001978-28 | A Multicenter, Randomized, Open-label, Phase 3 Trial Comparing LOXO-292 to Physicians Choice of Cabozantinib or Vandetanib in Patients with Progressive, Advanced, Kinase Inhibitor Naïve, RET-Mutant Me... | not-yet-due | |
| Ongoing, reported early | 2019-001979-36 | A Multicenter, Randomized, Open-label, Phase 3 Trial Comparing LOXO-292 to Platinum-Pemetrexed Chemotherapy Plus Investigator’s Choice of Pembrolizumab in Patients with Advanced, Treatment-Naïve RET F... | not-yet-due | |
| Exempt, with results | 2019-002318-37 | A Study to Assess the Pharmacokinetics, Glucodynamics, Safety, and Tolerability of LY900027 in Patients with Type 1 Diabetes Mellitus on Continuous Subcutaneous Insulin Infusion Therapy | 2020-07-14 | not-yet-due |
| Exempt | 2019-002319-25 | A Multi-Center Expanded Access Program (EAP) for the Treatment of Patients with Locally Advanced or Metastatic Solid Tumors with Rearranged During Transfection (RET) Activation (LIBRETTO-201) Progr... | not-yet-due | |
| Reported results Terminated | 2019-002495-13 | A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Phase 2 Crossover Study to Evaluate the Efficacy and Safety of LY3454738 in Adults with Chronic Spontaneous Urticaria Inadequately Controll... | 2020-11-24 | due-trials |
| Trial is outside EEC, and reported results | 2019-002603-17 | A Phase 1, Open-Label, Single-Dose Pharmacokinetic Study of Lasmiditan in Pediatric Patients With Migraine | bad-data | |
| Ongoing | 2019-002687-27 | A Phase 3, Multicenter, Open-Label, Long-Term Extension Study to Evaluate the Long-Term Efficacy and Safety of Mirikizumab in Patients with Crohn's Disease | not-yet-due | |
| Other | 2019-002735-28 | The Effect of Tirzepatide versus Dulaglutide on Major Adverse Cardiovascular Events in Patients with Type 2 Diabetes (SURPASS-CVOT) | not-yet-due | |
| Ongoing | 2019-002931-27 | A Phase 1b Dose Escalation Study of Abemaciclib in Combination with Temozolomide and Irinotecan (Part A) and Abemaciclib in Combination with Temozolomide (Part B) in Pediatric and Young Adult Patients... | not-yet-due | |
| Reported results | 2019-002932-10 | A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED TRIAL TO EVALUATE THE EFFICACY AND SAFETY OF LEBRIKIZUMAB IN PATIENTS WITH MODERATE-TO-SEVERE ATOPIC DERMATITIS | 2022-05-03 | due-trials |
| Listed as ongoing, but also has a completion date and reported results | 2019-002933-12 | A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED TRIAL TO EVALUATE THE EFFICACY AND SAFETY OF LEBRIKIZUMAB IN PATIENTS WITH MODERATE-TO-SEVERE ATOPIC DERMATITIS | 2022-04-28 | bad-data |
| Exempt | 2019-003159-12 | A Phase 1/2 Ascending Dose Study to Evaluate the Safety and Effects on Progranulin Levels of LY3884963 in Patients with Fronto-Temporal Dementia with Progranulin Mutations (FTD-GRN) (PROCLAIM) | not-yet-due | |
| Listed as ongoing, but also has a completion date | 2019-003323-38 | A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Study of LY3471851 (NKTR-358) in Adults with Systemic Lupus Erythematosus | 2023-02-16 | bad-data |
| Reported results | 2019-003339-53 | A Phase 2, Parallel, Comparator-Controlled Trial to Evaluate the Safety and Efficacy of LY3209590 in Insulin-Naïve Patients with Type 2 Diabetes Mellitus | 2021-10-08 | due-trials |
| Exempt | 2019-003581-41 | EMBER: A Phase 1a/1b Study of LY3484356 Administered as Monotherapy and in Combination with Anticancer Therapies for Patients with ER+ Locally Advanced or Metastatic Breast Cancer and Other Select Non... | not-yet-due | |
| Listed as ongoing, but also has a completion date and reported results | 2019-003589-41 | A Phase 2, Randomized, Parallel, Open-Label Comparator-Controlled Trial to Evaluate the Safety and Efficacy of LY3209590 in Study Participants With Type 1 Diabetes Mellitus Previously Treated With Mul... | 2021-10-01 | bad-data |
| Reported results | 2019-004300-34 | A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED TRIAL TO EVALUATE THE EFFICACY AND SAFETY OF LEBRIKIZUMAB WHEN USED IN COMBINATION WITH TOPICAL CORTICOSTEROID TREATMENT IN PATIENTS WITH MODERATE-TO-SEV... | 2021-09-16 | due-trials |
| Reported results | 2019-004301-28 | AN OPEN-LABEL, SINGLE-ARM STUDY TO ASSESS THE SAFETY AND EFFICACY OF LEBRIKIZUMAB IN ADOLESCENT PATIENTS WITH MODERATE-TO-SEVERE ATOPIC DERMATITIS | 2022-06-22 | due-trials |
| Ongoing | 2019-004378-24 | Pediatric Options for Migraine Relief: A randomized, double-blind, placebo-controlled study of lasmiditan for acute treatment of migraine | not-yet-due | |
| Other | 2019-004379-38 | A Phase 3, 12-Month, Open-Label Study of Lasmiditan in Pediatric Patients with Migraine | not-yet-due | |
| Other | 2020-000077-25 | Assessment of Safety, Tolerability, and Efficacy of Donanemab in Early Symptomatic Alzheimer’s Disease | not-yet-due | |
| Reported results | 2020-000284-23 | A Randomized, Phase 3, Open-label Trial Comparing the Effect of the Addition of Tirzepatide Once Weekly versus Insulin Lispro (U100) Three Times Daily in Participants with Type 2 Diabetes Inadequately... | 2022-11-01 | due-trials |
| Reported results | 2020-000290-24 | CYCLONE 1: A Phase 2 Study of Abemaciclib in Metastatic Castration-Resistant Prostate Cancer Patients Previously Treated with a Novel Hormonal Agent and Taxane-based Chemotherapy | 2023-06-02 | due-trials |
| Ongoing | 2020-001211-24 | A LONG-TERM STUDY TO ASSESS THE SAFETY AND EFFICACY OF LEBRIKIZUMAB IN PATIENTS WITH MODERATE-TO-SEVERE ATOPIC DERMATITIS | not-yet-due | |
| Listed as ongoing, but also has a completion date and reported results | 2020-001517-21 | A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Phase 3 Study of Baricitinib in Patients with COVID-19 Infection Studio di fase 3 randomizzato, in doppio cieco, controllato con place... | 2021-06-10 | bad-data |
| Reported results | 2020-002673-10 | A Phase 2 Study to Evaluate the Efficacy and Safety of LY3462817 in Participants with Moderately to Severely Active Rheumatoid Arthritis | 2022-06-29 | due-trials |
| Listed as ongoing, but also has a completion date and reported results | 2020-003017-35 | An Adaptive Phase 2, Randomized, Double-Blind, Placebo-Controlled Study of LY3471851 (NKTR-358) in Patients with Moderately to Severely Active Ulcerative Colitis | 2023-08-22 | bad-data |
| Listed as ongoing, but also has a completion date | 2020-004035-24 | eMonarcHER: A Randomized, Double Blind, Placebo-Controlled Phase 3 Study of Abemaciclib plus Standard Adjuvant Endocrine Therapy in Participants with High-Risk, Node-Positive, HR+, HER2+ Early Breast ... | 2024-06-26 | bad-data |
| Ongoing | 2020-004553-72 | A Phase 3 Open-Label, Randomized Study of LOXO-305 versus Investigator Choice of BTK Inhibitor in Patients with Previously Treated BTK Inhibitor Naïve Mantle Cell Lymphoma (BRUIN MCL-321) | not-yet-due | |
| Other | 2020-004554-30 | A Phase 3 Open-Label, Randomized Study of LOXO-305 versus Investigator's Choice of Idelalisib plus Rituximab or Bendamustine plus Rituximab in BTK Inhibitor Pretreated Chronic Lymphocytic Leukemia/Sma... | not-yet-due | |
| Other | 2020-005191-35 | LIBRETTO-432: A Placebo-controlled Double-Blinded Randomized Phase 3 Study of Adjuvant Selpercatinib following Definitive Locoregional Treatment in Participants with Stage IB-IIIA RET fusion-Positive ... | not-yet-due | |
| Other | 2020-005311-49 | Master protocol for a Phase 3, multicenter, open-label, long-term extension study to evaluate the long-term efficacy and safety of mirikizumab in children and adolescents with moderate-to-severe ulcer... | not-yet-due | |
| Other | 2021-000043-49 | A Phase 3 Open-Label, Randomized Study of Fixed Duration Pirtobrutinib (LOXO-305) plus Venetoclax and Rituximab versus Venetoclax and Rituximab in Previously Treated Chronic Lymphocytic Leukemia/Small... | not-yet-due | |
| Ongoing | 2021-000079-35 | EMBER-3: A Phase 3, Randomized, Open-Label Study of Imlunestrant, Investigator's Choice of Endocrine Therapy, and Imlunestrant plus Abemaciclib in Patients with Estrogen Receptor Positive, HER2 Negati... | not-yet-due | |
| Ongoing | 2021-000170-29 | Assessment of Safety, Tolerability, and Efficacy of LY3372689 in Early Symptomatic Alzheimer’s Disease | not-yet-due | |
| Trial is outside EEC, and reported results | 2021-000364-30 | A Phase 1 Study Of Ramucirumab, a Human Monoclonal Antibody Against the Vascular Endothelial Growth Factor-2 (VEGFR-2) Receptor in Children With Refractory Solid Tumors, Including CNS Tumors | bad-data | |
| Ongoing | 2021-001234-20 | A Phase 3 Open-Label, Randomized Study of Pirtobrutinib (LOXO-305) versus Bendamustine plus Rituximab in Untreated Patients with Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (BRUIN-CLL-313) | not-yet-due | |
| Other | 2021-001338-21 | A Multicenter, Open-Label, Pharmacokinetic and Safety Study of Baricitinib in Pediatric Patients from 1 Year to Less Than 18 Years Old Hospitalized with COVID-19 | not-yet-due | |
| Completed, report not yet due Terminated | 2021-001406-30 | A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel Group, Two Arm, Phase 2 Clinical Trial to Evaluate the Efficacy and Safety of LY3361237 to Treat Adults with At Least Moderately A... | 2023-12-29 | not-yet-due |
| Other | 2021-002301-10 | postMONARCH: A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study to Compare the Efficacy of Abemaciclib plus Fulvestrant to Placebo plus Fulvestrant in Participants with HR+, HER2-, Advanced... | not-yet-due | |
| Listed as ongoing, but also has a completion date | 2021-002569-16 | A Phase 3, Multicenter, Randomized, Parallel-Design, Open-Label Trial to Evaluate the Efficacy and Safety of LY3209590 Compared with Insulin Degludec in Participants with Type 2 Diabetes Currently Tre... | 2024-05-15 | bad-data |
| Reported results | 2021-002805-88 | A Phase 2 Study of Once-Daily LY3502970 Compared with Placebo in Participants Who Have Obesity or Are Overweight with Weight-Related Comorbidities | 2022-11-22 | due-trials |
| Reported results | 2021-002806-29 | A Phase 2 Study of Once-Daily LY3502970 Compared with Placebo and Once-Weekly Dulaglutide in Participants with Type 2 Diabetes Mellitus | 2022-09-30 | due-trials |
| Ongoing | 2021-003206-41 | A Phase 3 Open-Label, Randomized Study of Pirtobrutinib (LOXO-305) versus Ibrutinib in Patients with Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (BRUIN-CLL-314) | not-yet-due | |
| Ongoing | 2021-003612-31 | A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study with an Open-Label Extension Assessing the Efficacy, Safety, and Pharmacokinetics/Pharmacodynamics of Tirzepatide in Pediatric and Adolesc... | not-yet-due | |
| Completed, report not yet due | 2021-004551-16 | A Master Protocol to Investigate the Efficacy and Safety of Tirzepatide Once Weekly in Participants who have Obstructive Sleep Apnea and Obesity: A Randomized, Double-Blind, Placebo-Controlled Trial (... | 2024-03-28 | not-yet-due |
| Completed, report not yet due | 2021-004552-41 | A Master Protocol to Investigate the Efficacy and Safety of Tirzepatide Once Weekly in Participants who have Obstructive Sleep Apnea and Obesity: A Randomized, Double-Blind, Placebo-Controlled Trial (... | 2024-03-29 | not-yet-due |
| Other | 2021-004734-11 | A Randomized, Open-Label, Phase 2 Study Evaluating Abemaciclib in Combination with Irinotecan and Temozolomide in Participants with Relapsed or Refractory Ewing's Sarcoma | not-yet-due | |
| Other | 2021-005273-47 | Tirzepatide Study of Renal Function in People with Overweight or Obesity and Chronic Kidney Disease with or without Type 2 Diabetes: Focus on Kidney Hypoxia in Relation to Fatty Kidney Disease using M... | not-yet-due | |
| Listed as ongoing, but also has a completion date | 2021-005878-25 | A Phase 3, Parallel-Design, Open-Label, Randomized Controlled Study to Evaluate the Efficacy and Safety of LY3209590 as a Weekly Basal Insulin Compared to Insulin Glargine in Adults with Type 2 Diabet... | 2024-02-28 | bad-data |
| Completed, report not yet due | 2021-005891-21 | A Phase 3, Parallel-Design, Open-Label, Randomized Control Study to Evaluate the Efficacy and Safety of LY3209590 as a Weekly Basal Insulin Compared to Insulin Degludec in Insulin Naïve Adults with Ty... | 2024-04-10 | not-yet-due |
| Completed, report not yet due | 2021-005892-38 | A Phase 3, Multicenter, Randomized, Parallel-Design, Open-Label Study to Evaluate the Efficacy and Safety of LY3209590 as a Weekly Basal Insulin Compared with Insulin Degludec in Participants with Typ... | 2024-05-07 | not-yet-due |
| Trial is outside EEC, and reported results | 2021-006088-61 | An Open-Label, Multi-Center, Single-Dose Study to Assess the Safety, Tolerability, Pharmacodynamics, and Pharmacokinetics of Nasal Glucagon in Pediatric Patients with Type 1 Diabetes Aged 1 to <4 year... | bad-data | |
| Ongoing | 2022-000780-48 | A Phase 2, Randomized, Double-Blind, Placebo-Controlled Study to Investigate the Efficacy and Safety of LY3540378 in Adults with Worsening Chronic Heart Failure with Preserved Ejection Fraction (HFpEF... | not-yet-due | |
| Other | 2022-000811-29 | A Phase 3, Multicenter, Randomized, Platform Study of p19 Inhibition of the IL-23 Pathway to Establish Efficacy in Pediatric Crohn’s Disease Studio piattaforma di fase 3, multicentrico, randomizzat... | not-yet-due | |
| Trial is outside EEC | 2024-000081-22 | A Safety, Tolerability and Pharmacokinetic Study of Tirzepatide for the Treatment of Pediatric Participants (6 years to 11 years) with Obesity. | bad-data |